





3 | Microbial Genetics | Research Article

Hemin availability induces coordinated DNA methylation and gene expression changes in *Porphyromonas gingivalis*

Ricardo Costeira, ¹ Joseph Aduse-Opoku, ² Jon J. Vernon, ³ Francisco Rodriguez-Algarra, ⁴ Susan Joseph, ² Deirdre A. Devine, ³ Philip D. Marsh, ³ Vardhman Rakyan, ⁴ Michael A. Curtis, ² Jordana T. Bell ¹

AUTHOR AFFILIATIONS See affiliation list on p. 33.

ABSTRACT Periodontal disease is a chronic inflammatory disease in which the oral pathogen Porphyromonas gingivalis plays an important role. Porphyromonas gingivalis expresses virulence determinants in response to higher hemin concentrations, but the underlying regulatory processes remain unclear. Bacterial DNA methylation has the potential to fulfil this mechanistic role. We characterized the methylome of P. gingivalis, and compared its variation to transcriptome changes in response to hemin availability. Porphyromonas gingivalis W50 was grown in chemostat continuous culture with excess or limited hemin, prior to whole-methylome and transcriptome profiling using Nanopore and Illumina RNA-Seq. DNA methylation was quantified for Dam/Dcm motifs and all-context N6-methyladenine (6mA) and 5-methylcytosine (5mC). Of all 1,992 genes analyzed, 161 and 268 were respectively over- and under-expressed with excess hemin. Notably, we detected differential DNA methylation signatures for the Dam "GATC" motif and both all-context 6mA and 5mC in response to hemin availability. Joint analyses identified a subset of coordinated changes in gene expression, 6mA, and 5mC methylation that target genes involved in lactate utilization and ABC transporters. The results identify altered methylation and expression responses to hemin availability in P. qingivalis, with insights into mechanisms regulating its virulence in periodontal disease.

IMPORTANCE DNA methylation has important roles in bacteria, including in the regulation of transcription. *Porphyromonas gingivalis*, an oral pathogen in periodontitis, exhibits well-established gene expression changes in response to hemin availability. However, the regulatory processes underlying these effects remain unknown. We profiled the novel *P. gingivalis* epigenome, and assessed epigenetic and transcriptome variation under limited and excess hemin conditions. As expected, multiple gene expression changes were detected in response to limited and excess hemin that reflect health and disease, respectively. Notably, we also detected differential DNA methylation signatures for the Dam "GATC" motif and both all-context 6mA and 5mC in response to hemin. Joint analyses identified coordinated changes in gene expression, 6mA, and 5mC methylation that target genes involved in lactate utilization and ABC transporters. The results identify novel regulatory processes underlying the mechanism of hemin regulated gene expression in *P. gingivalis*, with phenotypic impacts on its virulence in periodontal disease.

KEYWORDS oral biology, periodontal disease, virulence, iron availability, DNA methylation, gene expression

Teeth are secured in the mouth through the periodontal ligament, which is attached to the subgingival root surface and the alveolar bone. Periodontal disease is a common chronic inflammatory disease of the periodontal tissues that is driven by bacteria in subgingival microbial biofilms on the root surface. In periodontal disease,

Editor Tricia A. Van Laar, California State University, Stanislaus, Turlock, California, USA

Address correspondence to Michael A. Curtis, mike.curtis@kcl.ac.uk, or Jordana T. Bell, jordana.bell@kcl.ac.uk.

Ricardo Costeira and Joseph Aduse-Opoku contributed equally to this article. Order of authors was agreed by mutual discussion.

Michael A. Curtis and Jordana T. Bell contributed equally to this article.

The authors declare no conflict of interest.

See the funding table on p. 34.

Received 2 December 2022 Accepted 12 April 2023 Published 12 July 2023

Copyright © 2023 Costeira et al. This is an openaccess article distributed under the terms of the Creative Commons Attribution 4.0 International license.

July/August Volume 8 Issue 4

the integrity of the attachment tissues becomes compromised leading to bleeding, gingival recession, formation of deep periodontal pockets, and periodontal bone loss, ultimately culminating in tooth loss in a susceptible host. Periodontitis is a global health issue affecting both developed and developing nations (1). Furthermore, periodontitis is also associated with a range of extra-oral inflammatory conditions, such as diabetes and cardiovascular disease, rheumatoid arthritis, Alzheimer's disease, and pregnancy complications (2-4).

During the progression from health to periodontal disease, the oral microbiota undergoes a major transition wherein the microbial community increases in total bacterial diversity, accompanied by a bloom in disease-associated bacteria that start to dominate the community, while being otherwise present in low numbers in healthy microbiota (5, 6). Porphyromonas gingivalis, a black-pigmenting anaerobic rod bacterium, is well established as one of the organisms, which is positively associated with this shift to a dysbiotic microbiota in disease. Indeed, P. gingivalis has been shown to act as a trigger for the conversion of the subgingival microbiota to a more diverse and more pathogenic community in animal models of disease (5, 6). This keystone pathogen behavior has been attributed to the expression of a variety of extracellular virulence determinants including those trafficked through a type IX secretion system (T9SS) and through the production of large numbers of outer membrane vesicles, which are collectively able to destabilize the host-microbe homeostasis at this mucosal surface (7, 8).

Hemin, iron (III) protoporphyrin IX chloride, is a major source of iron for a variety of organisms, including P. gingivalis, where it is an essential co-factor for growth. Porphyromonas gingivalis has a dedicated transport system to ensure an efficient accumulation of hemin on the surface for iron utilization. Subsequent conversion of hemin to μ-οχο bishaem, and its complexation with iron III, leads to black pigmentation of the bacterial cells, a prominent characteristic of P. gingivalis on solid media containing blood (9). Porphyromonas gingivalis HmuY and HusA are dedicated, surface-exposed, hemophorelike proteins that scavenge and bind hemin, free or released from heme-containing proteins by gingipain proteases. The complexes deliver the bound heme to outer-membrane receptors (HmuR or HusB) for internalization, and heme is then imported through a dedicated TonB-dependent transport machinery (10).

The concentration of environmental hemin acts as a regulator of virulence in this bacterium: cells cultured in high concentrations of hemin—comparable to the situation in a diseased periodontium with elevated bleeding—upregulate the expression of a wide variety of virulence determinants, including a range of hydrolytic enzymes such as the gingipain cysteine proteases, and other protein products, many of unknown function (11, 12). High-hemin grown cells are significantly more pathogenic in animal models of tissue destruction compared to cells grown under hemin limitation (7, 13–15). Hence, the availability of hemin in the growth media is critical to the full expression of virulence of P. gingivalis, and hemin may be regarded as a global regulator of transcription in this bacterium. Although previous studies have characterized the impact of hemin availability on gene expression and virulence in P. gingivalis, the regulatory processes underlying these functional changes are not well understood. However, the P. gingivalis ATCC33277 genome encodes seven two-component signal transduction system (TCS) pairs of a response regulator and a histidine kinase traditionally involved in gene regulation in other organisms (16). Recently, it has been reported that one of these TCS, PorX/PorY, responds to environmental hemin and, through the co-ordinated action of PorX and SigP, regulates transcription of the T9SS and hemin accumulation; mutants defective in either porX or porY are attenuated in a mouse model of virulence (17, 18). However, given the magnitude of changes in response to the concentration of hemin, there may be other mechanisms of hemin-regulated gene expression in *P. gingivalis*.

Like eukaryotic genomes, bacterial genomes are subject to epigenetic modifications, specifically DNA methylation, which has multiple roles in bacteria including the regulation of transcription. Bacterial DNA methylation includes modifications

N6-methyladenine (6mA), 5-methylcytosine (5mC), and N4-methylcytosine (4mC), of which 6mA is most prevalent in prokaryotes. Recent development in single-molecule sequencing technologies, for example, Nanopore sequencing, allows for the detection of these multiple DNA methylation base modifications. Using this approach, bacterial DNA methylation signatures have recently been shown to impact gene expression profiles and genome stability (19, 20).

In this study, we investigated the impact of hemin availability on the *P. gingivalis* epigenome and transcriptome. *Porphyromonas gingivalis* W50 was grown in controlled conditions, in continuous culture at a constant pH and identical growth rates, under either limited hemin or excess hemin conditions previously associated with virulence changes in the same system (21). Subsequently, DNA sequencing using Nanopore and RNA sequencing using Illumina were carried out to profile the *P. gingivalis* DNA methylome and transcriptome under each condition. Hemin-dependent differentially modified signatures were identified for gene expression, as well as for 6mA and 5mC DNA methylation profiles both in Dam/Dcm motifs and genome wide. Comparison of the signals highlighted a cluster of coordinated changes in six genes, including in genes related to lactate utilization and in ABC transporters.

MATERIALS AND METHODS

Continuous culturing conditions

Strain culture

Porphyromonas gingivalis W50 was cultured on Columbia blood agar (CBA; Oxoid, UK) supplemented with 5% oxalated horse blood (Oxoid) incubated anaerobically (5% $CO_2/5\%$ $H_2/90\%$ N_2) at 37°C for 72 h. A single colony was inoculated into 100 mL of prereduced Brain Heart Infusion (BHI; Oxoid) broth supplemented with 5 mg L⁻¹ filter sterilized (0.22 μ M) hemin and incubated until late log phase (48–72 h).

Continuous culture chemostat configuration

A 1-L, sealed glass chemostat was autoclave sterilized with 300 mL BHI in situ. One hundred milliliters of P. gingivalis culture was inoculated into the chemostat through a designated inoculation tube, using a peristaltic pump (Watson Marlow 101U). Sterile BHI (supplemented with either 0.2 or 5 mg L⁻¹ hemin for limited and excess conditions, respectively) was continuously fed at a flow rate of 20 mL h⁻¹ to achieve the working volume of 700 mL, before being increased to 70 mL h⁻¹, in conjunction with harvest/waste pump activation at the equivalent rate. These conditions set a fixed dilution rate of 0.1 h⁻¹, which corresponds to constant mean generation time of 6.9 h. Steady state conditions were achieved after approximately 10 mean generations. Environmental conditions were controlled/monitored using an Applikon ADI 1030 Bio-controller and BioXpert V2 software (Applikon Biotechnology, The Netherlands). Environmental conditions were controlled for included nutrients, temperature, oxygen, and pH. The pH of the culture was maintained automatically at pH7±0.1 using 1 M NaOH and 0.5 M HCl fed through a peristaltic pump. Temperature was preserved at 37 \pm 0.3°C with a silicon heat jacket. The chemostat was continuously sparged with filter-sterilized 5% CO₂/95% N₂ to maintain anaerobic conditions and stirred at 40 rpm (Motor Controller ADI 1012, Applikon Biotechnology; Supplemental Note, Figure A).

Experimental design

independent chemostat experiments were performed, one with 5 mg L⁻¹ hemin (excess) and one with 0.2 mg L^{-1} hemin (limitation).

Post-inoculation, the optical density (OD₆₀₀) of the culture was monitored every 12 h using a benchtop spectrophotometer (Jenway 6305). Steady state was defined as three consecutive OD₆₀₀ readings within 10% of each other. Total viable counts and culture purity were determined daily, following serial dilutions in phosphate buffered saline, inoculation of CBA plates in triplicate, and growth in a Whitley A45 anaerobic Workstation (Don Whitley Scientific, UK). Sampling for DNA and RNA analysis was performed every 48 h during steady state (Fig. 1). This represented biological replicates separated by five full-volume replenishments of the chemostat vessel. Overall, three biological replicates were collected for each condition, with each one of the replicates collected at one sampling point (days 10, 12, and 14).

Nucleic acid sampling

During nucleic acid sampling periods, the harvest bottle was replaced with a sterile collection bottle (on ice) and approximately 20 mL was collected. For DNA sampling, 1 mL aliquots were centrifuged at 13,000 rpm for 10 min (4°C), prior to supernatant removal and storage at -80°C. For RNA samples, ten 1-mL samples were similarly centrifuged, the supernatant decanted, and the pellet reconstituted in 1 mL of DNA/RNA Shield (Zymo Research, USA) prior to storage at -80°C.

DNA extraction

One-milliliter cultures were centrifuged at 17,000×g, at 4°C for 10 min. The pellets were used to extract high molecular weight DNA using Gentra Puregene yeast/bacteria DNA isolation kit (Qiagen, Germany), following the manufacturer's protocol. DNA was finally resuspended in 200-µL EB buffer (Qiagen) and stored at 4°C before use.

RNA extraction

Cells were pelleted as above and resuspended/lysed in 350 µL of DNA/RNA Shield (Cambridge Biosciences, UK) at room temperature. The solutions were used directly in RNA isolation with Zymo Quick-RNA miniprep kit (Cambridge Biosciences) in accordance with the manufacture's protocol. This incorporated the initial chromosomal DNA removal and on-column DNAase I digestion before the final wash and elution into 50 µL nucleasefree water. RNA was stored at -70°C.




FIG 1 Timeline of Porphyromonas gingivalis W50 chemostat operation and experimental design. BHI, Brain Heart Infusion, CFU, colony forming unit.

Illumina RNA sequencing

RNA samples were first subjected to rRNA depletion using the NEBNext rRNA Depletion Kit (Bacteria) (New England Biolabs, USA). The samples were then used for RNA-Seq library preparation using the NEBNext Ultra II Directional RNA Library Prep Kit for Illumina. Both kits were used according to the manufacturer's instructions. Sequencing was performed by Novagene, UK on an Illumina Novaseg6000 instrument.

Oxford Nanopore DNA sequencing

Minlon library preparation and DNA sequencing was performed at the University of Nottingham on Minlon flow cell (Oxford Nanopore, UK). Whole-genome sequencing libraries were prepared from six bacterial genomic DNA samples. DNA samples were quantified using the Qubit 4 Fluorometer (Thermo Fisher Scientific, USA) and the Qubit dsDNA BR Assay Kit (Thermo Fisher Scientific; Q32853), and the Agilent 4200 TapeStation and the Agilent Genomic DNA ScreenTape Assay (Agilent, USA; 5067-5365 and 5067-5366) were used to assess the molecular weight of the DNA. Sequencing libraries were prepared using the Native barcoding genomic DNA protocol (Oxford Nanopore Technologies; Version: NBE_9065_v109_revS_14Aug2019). This protocol uses the Ligation Sequencing Kit (Oxford Nanopore Technologies; SQK-LSK109) and the Native Barcoding Expansion 1-12 kit (Oxford Nanopore Technologies; EXP-NBD104) to barcode the unsheared DNA fragments within each sample. Barcoded samples were then pooled in equimolar amounts for the final sequencing adapter ligation. All purification steps were performed using AMPure XP beads (Beckman Coulter; A63882). The final barcoded library pool was loaded onto a MinION flow cell (Oxford Nanopore Technologies; FLO-MIN106 R9.4.1) and run on the GridION X5 Mk1.

Bioinformatic analyses

RNA sequencing data processing

Sequencing data were processed using the ProkSeg pipeline v2.8 (22) Briefly, FastQC (23) and AfterQC (24) were implemented to check the quality of data, trim adaptor sequences, and filter out low-quality reads using standard parameters. This resulted in a total of \approx 25.3–36.0 M PE reads (2 \times 76 bp) being kept for downstream processing. Subsequently, bowtie2 (25) was used to align reads against the 104 contigs of the P. gingivalis W50 genome assembly deposited in the NCBI RefSeg (accession no. GCF 000271945.1). RefSeg gene annotations were extracted from P. gingivalis' GTF file, and the number of total reads per gene were calculated using featureCounts (26). Counts per gene were estimated for 1,992 genes. RSeQC (27) was used to study sample coverage uniformity along the body of genes.

DNA methylation calling

Motif-dependent DNA methylation calling

Modified basecalling was first performed with Guppy v3.2.10+aabd4ec (Oxford Nanopore) using the high-accuracy methylation-aware configuration available for Dam and Dcm motifs from Escherichia coli ('dna_r9.4.1_450bps_modbases_dam-dcmcpg hac.cfg'). Total Nanopore read data included ≈240–380 K reads (88 bp – 143 kb, N50 = 27 kb) per sample. Methylated and canon bases were then aggregated against the P. qinqivalis W50 reference genome using Medaka v0.11.5 (https://github.com/nanoporetech/medaka). Base counts were normalized for the total number of reads in each sample \times 10,000 reads in similar fashion to the RPG10K method (28, 29). The proportion of methylated bases to the total number of bases (methylated + canon bases) was estimated at each genomic motif, and motifs were filtered for minimum 10x coverage across samples. A total of 12,066 "GATC" (Dam), 419 "CCAGG" (Dcm), and 400 "CCTGG" (Dcm) motifs were kept for downstream analyses.

Motif-independent DNA methylation calling

Nanopore signals were originally stored in multi-read fast5 files, and the ont_fast5_api "multi to single fast5" (https://github.com/nanoporetech/ont_fast5_api) was used to generate single fast5 files before detection of non-standard nucleotides with Tombo v1.5.1 (30). First, electric current signal level data were re-squiggled using the same P. gingivalis W50 reference genome used to preprocess the RNA-Seg and methylated motif data. Secondly, all-context motif-independent models were used in Tombo to detect the alternative bases 6mA and 5mC from the signal data. Alternative basecalling in each sample was summarized per genomic position with coverage and dampened fractions estimated at each adenine and cytosine site of both positive and negative DNA strands. Coverage was stored in the bedGraph format and proportion of methylation in the WIG format. Data files were imported into R using the package rtracklayer (31) and combined into a single data frame using GRanges, IRanges, and findOverlaps from the IRanges package (32).

The proportion of methylation—dampened fraction—was estimated by adjusting the proportion of methylated reads according to coverage at low-coverage sites in order to include them in downstream analyses (30). Despite this, only adenines and cytosines with at least 10× coverage across samples were included in our analysis here as well. Overall, 1,150,659 adenines and 1,079,809 cytosines were kept for downstream analyses, with 350-525× mean base coverage per sample.

Statistical analyses

Differential gene expression analysis

DESeq2 (33) was used to normalize the read count data and perform differential gene expression analysis. Growth in limited hemin was the "control" and growth in excess hemin was the "treatment." All three samples from each condition were used, and global sample differences were observed using the principal component analysis (PCA) method. Both DESeq2 and edgeR (34) were implemented from ProkSeq's downstream analysis. Both methods allow for inter-sample comparison in differential gene expression analysis. Here, we used edgeR results as sensitivity for DESeq2 results since edgeR normalizes expression data differently from DESeq2 (DESeq2 uses the median of ratios method, and edgeR uses the trimmed mean of M values to normalize read count data). The false discovery rate (FDR) method was used to identify differentially expressed genes (DEGs) and genes with FDR <5%, and a log₂ fold change (LFC) >1.5 or <-1.5 were respectively considered over and under-expressed in excess hemin. DEGs were subsequently manually annotated to the P. aingivalis W83 genome (GenBank accession no. AE015924) (35) in order to compare results with previous research. Synteny analysis at specific loci was performed using MAUVE (36).

Gene ontology enrichment analysis

Gene ontology (GO) enrichment analysis in over and under-expressed gene sets was performed using ShinyGO (37). Because the genome of P. gingivalis W50 was not available from ShinyGO's species database, only well-characterized genes that matched gene symbols in P. gingivalis W83 reference strain genome were used in this analysis. A more relaxed FDR threshold of 10% was applied to assess enrichment in this case and GO molecular functions were reported.

Differential DNA methylation analysis

Mean and median DNA methylation across samples were calculated using all motifs, adenines, and cytosines kept for downstream analysis. Global DNA methylation differences between the samples were observed using PCA for Dam/Dcm and all-context 6mA and 5mC modifications, selecting for minimum 10x and 100x coverage per position.

Two-sided Student's t-tests were applied at each motif, adenine, and cytosine site after filtering for positions where at least a 5% mean methylation difference was observed between the experimental conditions [79 "GATC" motifs (Dam), 139,794 all-context adenines, and 87,398 all-context cytosines]. A sensitivity analysis was performed for minimum 100× coverage [66 "GATC" motifs (Dam), 85,090 all-context adenines, and 46,930 all-context cytosines] to ascertain whether the significance of results was impacted by depth of sequencing. Results were considered statistically significant at an FDR threshold of 5% to match gene expression analysis.

The differentially methylated motifs and all-context positions identified were annotated to nearby genes considering the location and gene strand. First, differentially methylated "GATC" motifs ("GATC"-DMMs), differentially methylated adenine sites (DMAs), and differentially methylated cytosines (DMCs) were annotated to the gene they were located if present in the gene body, and secondly, they were annotated to genes found in the same contig and within ± 1 kb of their location. Genes located in the opposite strand of the methylation signal were considered in both cases.

In comparing the overlap between DEGs, DMA, DMCs, and "GATC"-DMMs, we considered all DMAs, DMCs, and "GATC"-DMMs that were in or near the gene (±1 kb away, both strands). DMA and DMC data were further used to test the wider DNA methylation effects on the expression of nearby genes. A contingency table containing all 1,992 genes was constructed, and Fischer's exact tests were employed to test for the enrichment of genes with concurrent gene expression and all-context DNA methylation changes. The enrichment of differential DNA methylation directly upstream, downstream, and in the body of genes was also tested. Here, Wilcoxon signed-rank tests were used to test for generalized shifts in DNA methylation signals between the experimental conditions at sites 100 bp upstream, 100 bp downstream, and within the body of genes previously annotated to DMAs and/or DMCs.

Motif enrichment analysis

The MEME (Multiple EM for Motif Elicitation) online tool (38) was used to detect enriched motifs containing the DMAs and DMCs identified with concurrent gene expression changes. For this, 15 base pair long DNA sequences surrounding the DMAs and DMCs identified were extracted. Subsequently, motifs with minimum 4 bp and maximum 15 bp were searched using MEME's Classic objective function and the ZOOPS distribution model. Both the given strand and the reverse complement strand were considered, and the top 10 motifs found were reported. Motifs were considered significant if their reported E-value threshold was ≤0.05.

RESULTS

Gene expression and DNA methylation profiling of P. gingivalis W50 was performed after culturing in chemostat runs with excess (5 mg L⁻¹) or limited hemin (0.2 mg L⁻¹). The dose-response curve of P. gingivalis' exposure to hemin was previously determined by us (15), where we showed that 0.2 mg L^{-1} of hemin limits *P. gingivalis'* growth and 5 mg L^{-1} of hemin results in excess hemin. We chose to use chemostats for these studies because this approach provides cells at a physiological steady state under constant environmental conditions. Growth of P. gingivalis in both high and low hemin was at a constant specific growth rate, and all culture parameters remained constant with the exception of the concentration of hemin. Biological replicates were collected every 48 h after achieving steady state, with three independent biological replicates per experimental condition profiled using Illumina RNA-Seq and Nanopore DNA sequencing technologies (Fig. 1).

Continuous chemostat environment

Steady state was achieved by days 3 and 4 for excess and limited hemin (Fig. 2), respectively. Colony counts of P. gingivalis W50 were consistently higher in excess hemin




FIG 2 Enumeration of Porphyromonas gingivalis populations throughout the continuous culture chemostat experimental duration by colony count and optical density (OD). Porphyromonas gingivalis W50 cultured with excess (5 mg L⁻¹) and limited (0.2 mg L⁻¹) hemin. RNA and DNA samples were taken at days 4, 6, and 8. Vertical green dashed line represents the point of steady state, as determined by OD600 measurement. Error bars represent standard error of the mean. CFU, colony forming units.

culture [mean = 1.89×10^9 colony forming units (CFU mL⁻¹), range $5.07 \times 10^8 - 3.27 \times 10^9$ CFU mL⁻¹] versus limitation (mean = 1.80×10^8 CFU mL⁻¹, range 1.63×10^8 – 2.05×10^8 CFU mL^{-1}). OD₆₀₀ ranged between 1.67–1.72 (mean 1.69) and 0.357–0.376 (mean 0.367) for excess and limited hemin, respectively. The pH was automatically controlled at pH 7.0 ± 0.1, while temperature remained between 36.7 and 37.1°C for both conditions. Bacteria were grown at an identical and constant growth rate of 6.9 h mean generation time under both conditions (15).

Gene expression changes

RNA-Seq data for the six samples was processed using ProkSeq (22) and DESeq2 (33) to assess gene expression changes observed after culturing P. gingivalis W50 in excess (treatment) and limited (control) hemin conditions. These results were mapped to the P. gingivalis W50 genome (RefSeq assembly accession no. GCF_000271945.1). The expression data captured all 1,992 previously annotated genes, and those with an expression LFC >1.5 or LFC <-1.5 were considered differentially expressed after multiple testing correction at FDR = 5%. Altogether, 161 and 268 DEGs were respectively overand under-expressed in excess hemin across the P. gingivalis genome (Fig. 3).

The 161 DEGs over-expressed in excess hemin included genes encoding homologous proteins of the rubrerythrin family (HMPREF1322_RS04040), iron-sulfur cluster domain-contain containing proteins (e.g., HMPREF1322_RS09700), a thiamine phosphate synthase (HMPREF1322_RS02110), electron transport complex subunits (e.g., HMPREF1322_RS04875, HMPREF1322_RS04865, and HMPREF1322_RS04880), oxidoreductases HMPREF1322 RS07305 family/ferredoxin (e.g., HMPREF1322_RS04445), and several dehydrogenases (Table 1; Table S1). Most of these genes encode proteins that contain iron as part of their tertiary structure. Three operonic genes, originally labelled as encoding TapA, TapB, and TapC (39),




FIG 3 Differentially expressed genes in excess hemin conditions. Porphyromonas qinqivalis genes were considered differentially expressed if transcript abundance surpassed 1.5 log2 fold change between culturing conditions (false discovery rate = 5%).

HMPREF1322_RS02140, HMPREF1322_RS02145, and HMPREF1322_RS02150, respectively, were also over-expressed. TapA, TapB, and TapC contribute to virulence in a mouse model as single isogenic mutants are attenuated. Both TapA and TapC exhibit the C-terminal domain (CTD) signature typical of the T9SS, and are therefore cargo proteins as are the proteases HMPREF1322_RS06795 (PrtT) and Lys-gingipain (Kgp).

The 268 DEGs under-expressed in excess hemin included genes hmuY (heminbinding), HMPREF1322_RS06790 (hemin transport), and those encoding homologues of at least 35 transposases (e.g., HMPREF1322_RS07370, HMPREF1322_RS07285, HMPREF1322_RS10850) (Table 2; Table S2). Other genes under-expressed in excess hemin conditions included genes coding several transporter proteins, with at least eight genes coding ABC transporter proteins (e.g., HMPREF1322_RS00745, HMPREF1322_RS00115, HMPREF1322_RS08925). The gene encoding the largest protein component of the T9SS, Sov (SprA), and also genes encoding OmpH, PorN (GldN) and PorX along with five cargo proteins, were under-expressed in excess hemin (Table S2).

Different types of genes involved in virulence were identified in both the under- and over-expressed DEG subsets. For example, these included different types of N-acetylmuramoyl-L-alanine amidase genes, T9SS type A sorting domain-containing protein genes and MATE family efflux transporter genes, and tetratricopeptide repeat protein genes (Tables S1 and S2). Additionally, methyltransferase genes were also identified in both the over- and under-expressed DEG subsets (e.g., tRNA and 16S rRNA methyltransferases, and class I SAM-dependent methyltransferases, respectively).

We explored molecular functions shared across the DEGs, although a proportion of genes were not well characterized. Sixty-seven under-expressed (25% of total) and 19 over-expressed (12%) genes identified during growth in excess hemin encoded hypothetical proteins. Additionally, only 16 (6%) of under-expressed genes and 49 (30%) of over-expressed genes identified had well-characterized annotations in RefSeq. A GO term enrichment analysis was carried out using ShinyGO and gene symbols that matched genes in the reference strain P. gingivalis W83 (35), with altogether 8 (out of 16 well-characterized) under-expressed and 40 (out of 49 well-characterized) overexpressed genes. Forty-two and 43 GO molecular functions were respectively enriched in genes under- and over-expressed in excess hemin conditions. In both cases, molecular functions identified were mostly related to binding activities such as cyclic compound binding, heterocyclic compound binding, and ion binding (Fig. 4; Tables S3 and S4). In excess hemin, functions related to Fe-S cluster binding, 4Fe-4S cluster binding, and metal cluster binding, and several different catalytic activities, including GTPase,

TABLE 1 Genes most over-expressed in excess hemin conditions ordered by P-value^a

Locus tag	baseMean	LFC	IfcSE	<i>P</i> -value	Gene symbol	Gene product
HMPREF1322_RS04040	36,595.19	3.51	0.22	5.16E-55	-	Rubrerythrin family protein
HMPREF1322_RS09700	10,401.67	5.11	0.38	7.99E-42	-	4Fe-4S dicluster domain-containing protein
HMPREF1322_RS02110	21,476.06	5.74	0.48	4.96E-33	-	Thiamine phosphate synthase
HMPREF1322_RS04875	4,568.08	3.08	0.29	1.10E-26	-	RnfABCDGE type electron transport complex subunit G
HMPREF1322_RS09380	6,878.27	3.42	0.34	1.63E-24	-	tRNA-Ala
HMPREF1322_RS01360	88,636.17	2.13	0.21	2.51E-23	kgp	Lys-gingipain
HMPREF1322_RS07500	8,156.19	3.17	0.32	3.27E-23	-	FtsX-like permease family protein
HMPREF1322_RS04865	8,535.61	2.89	0.29	6.34E-23	rsxC	Electron transport complex subunit RsxC
HMPREF1322_RS07540	5,351.44	2.19	0.23	5.24E-22	dnaA	Chromosomal replication initiator protein DnaA
HMPREF1322_RS01760	8,591.86	2.00	0.21	2.09E-21	-	Electron transfer flavoprotein subunit alpha/FixB family protein
HMPREF1322_RS02075	76,668.23	2.38	0.25	7.17E-21	rpsO	30S ribosomal protein S15
HMPREF1322_RS07695	18,257.75	2.38	0.26	1.73E-20	-	50S ribosomal protein L28
HMPREF1322_RS07305	39,671.02	3.52	0.38	3.70E-20	-	SDR family oxidoreductase
HMPREF1322_RS06590	3,693.30	2.34	0.26	7.00E-20	-	Lipoprotein signal peptidase
HMPREF1322_RS04880	1,646.03	2.96	0.33	7.77E-20	-	Electron transport complex subunit E
HMPREF1322_RS07315	10,873.97	2.21	0.24	2.04E-19	pdxA	4-Hydroxythreonine-4-phosphate dehydrogenase PdxA
HMPREF1322_RS02115	802.74	3.67	0.41	3.12E-19	-	Thiazole synthase
HMPREF1322_RS04430	6,944.22	2.67	0.30	4.81E-19	vorB	3-Methyl-2-oxobutanoate dehydrogenase subunit VorB
HMPREF1322_RS06505	6,503.86	2.28	0.26	4.99E-19	-	Succinate dehydrogenase/fumarate reductase cytochrome b
						subunit
HMPREF1322_RS01420	4,037.78	2.32	0.27	2.55E-18	-	Peptide chain release factor 2
HMPREF1322_RS06515	17,162.15	1.98	0.23	4.65E-18	-	Succinate dehydrogenase/fumarate reductase iron-sulfur
						subunit
HMPREF1322_RS06545	9,763.98	2.91	0.35	5.41E-17	-	Sodium ion-translocating decarboxylase subunit beta
HMPREF1322_RS07560	1,584.83	1.91	0.23	6.14E-17	-	Hypothetical protein
HMPREF1322_RS04870	2,568.12	2.33	0.28	7.12E-17	-	RnfABCDGE type electron transport complex subunit D
HMPREF1322_RS09385	113,129.22	4.77	0.57	7.41E-17	-	tRNA-lle
HMPREF1322_RS01415	5,871.99	1.89	0.23	8.89E-17	-	Long-chain fatty acid—CoA ligase
HMPREF1322_RS04445	1,892.04	2.05	0.25	1.71E-16	-	2-Oxoglutarate ferredoxin oxidoreductase subunit gamma
HMPREF1322_RS03105	19,942.29	2.37	0.29	2.99E-16	mazG	Nucleoside triphosphate pyrophosphohydrolase
HMPREF1322_RS02105	2,652.52	2.90	0.36	6.36E-16	thiC	Phosphomethylpyrimidine synthase ThiC
HMPREF1322_RS07295	918.07	2.53	0.32	1.25E-15	_	Hypothetical protein

The complete list of 161 genes is included in Table S1. LFC, log2 fold change; lfcSE, standard error of log2 fold change.

metallo-endopeptidase, active transmembrane transporter, and diphosphotransferase activities, were also identified (Fig. 4; Table S4).

Two sensitivity analyses were carried out for the genome-wide DESeg2 DEG results presented here. A first sensitivity analysis was performed using edgeR, which normalizes expression data differently from DESeq2, and consistently identified the majority of DEGs identified with DESeq2 (Supplemental Note, Figure B). Specifically, edgeR identified 166 genes as over-expressed and 266 genes as under-expressed with excess hemin, of which 161 and 265 were previously identified with DESeq2. In a second general sensitivity analysis, a PCA of the genome-wide RNA-seq levels also confirmed overall global differences in gene expression levels between the culturing conditions (Supplemental Note, Figure C).

DNA methylation changes

Nanopore sequencing data were generated for the same six biological samples analyzed with Illumina RNA sequencing. Dam- and Dcm-dependent methylation was characterized using the Guppy basecaller. A total of 12,066 "GATC" (Dam) and 819 "CCWGG" (Dcm) motifs with minimum 10× coverage across samples were considered. Motif-independent methylation levels for 6mA and 5mC were characterized using Tombo with "all-context"

TABLE 2 Genes most under-expressed in excess hemin conditions (or most over-expressed in limited hemin conditions) ordered by P-value^a

Locus tag	baseMean	LFC	IfcSE	P-value	Gene symbol	Gene product
HMPREF1322_RS06000	19,212.04	-7.71	0.27	1.21E-184	_	TetR/AcrR family transcriptional regulator
HMPREF1322_RS06010	7,387.12	-8.06	0.28	5.34E-183	_	Outer membrane lipoprotein-sorting protein
HMPREF1322_RS06015	24,454.31	-7.46	0.28	2.46E-160	_	Hypothetical protein
HMPREF1322_RS06005	47,425.12	-7.36	0.30	1.87E-133	_	MMPL family transporter
HMPREF1322_RS05430	7,754.25	-5.44	0.23	7.95E-121	_	Flavodoxin
HMPREF1322_RS06790	15,141.08	-6.11	0.30	3.67E-92	_	Heme-binding protein HmuY
HMPREF1322_RS04145	4,231.05	-5.42	0.29	7.09E-76	_	DUF4876 domain-containing protein
HMPREF1322_RS00165	33,997.53	-3.86	0.24	3.60E-60	_	Hypothetical protein
HMPREF1322_RS08955	18,702.05	-3.75	0.23	6.92E-59	_	PgIZ domain-containing protein
HMPREF1322_RS03170	5,510.46	-5.17	0.32	2.13E-57	_	T9SS type A sorting domain-containing protein
HMPREF1322_RS00745	3,619.54	-4.27	0.27	2.40E-57	_	ABC transporter ATP-binding protein
HMPREF1322_RS00465	1,031.56	-4.52	0.29	2.04E-55	_	DUF3575 domain-containing protein
HMPREF1322_RS03855	47,852.31	-3.81	0.25	8.15E-51	_	T9SS type A sorting domain-containing protein
HMPREF1322_RS05045	1,138.34	-4.32	0.29	5.25E-50	_	Hypothetical protein
HMPREF1322_RS07370	25,172.29	-3.07	0.21	1.50E-47	_	Transposase
HMPREF1322_RS05050	901.14	-3.69	0.26	5.74E-47	_	Hypothetical protein
HMPREF1322_RS04140	4,263.72	-5.40	0.39	9.54E-44	_	TonB-dependent receptor
HMPREF1322_RS07285	4,362.71	-3.54	0.26	1.81E-42	_	IS5/IS1182 family transposase
HMPREF1322_RS00730	1,091.42	-3.38	0.25	5.01E-41	_	Hypothetical protein
HMPREF1322_RS10850	767.65	-3.04	0.23	6.51E-41	_	IS5/IS1182 family transposase
HMPREF1322_RS05700	1,363.75	-2.92	0.22	6.42E-39	_	IS5/IS1182 family transposase
HMPREF1322_RS02830	245.42	-3.57	0.27	1.53E-38	_	Helix-turn-helix domain-containing protein
HMPREF1322_RS08255	1,559.13	-2.94	0.23	2.65E-38	_	IS5/IS1182 family transposase
HMPREF1322_RS00725	911.64	-2.93	0.23	5.26E-38	_	Lactate utilization protein
HMPREF1322_RS05425	530.83	-3.76	0.29	1.83E-37	_	DUF2023 family protein
HMPREF1322_RS00485	425.30	-3.46	0.27	2.24E-37	_	DUF4906 domain-containing protein
HMPREF1322_RS07380	45,140.22	-3.08	0.24	3.93E-37	_	OmpH family outer membrane protein
HMPREF1322_RS08605	2,232.06	-4.56	0.36	4.87E-37	_	Co-chaperone GroES
HMPREF1322_RS07630	1,708.56	-3.97	0.31	5.27E-37	_	cCass I SAM-dependent methyltransferase
HMPREF1322_RS04045	1,062.32	-2.77	0.22	1.27E-36	_	IS982 family transposase

 $^{{\}it ^o} The\ complete\ list\ of\ 268\ genes\ is\ included\ in\ Table\ S2\ LFC,\ log2\ fold\ change;\ lfcSE,\ Standard\ error\ of\ log2\ fold\ change.$

models, considering >2M positions with a minimum $10\times$ coverage. PCA of the genome-wide DNA methylation levels pointed to both global 6mA and 5mC differences in *P. gingivalis* according to hemin culture conditions [Supplemental Note, Figure D(A)], and mirrored the PCA pattern observed for gene expression (Supplemental Note, Figure C). Similar results were observed when considering signals with at least $100\times$ coverage [Supplemental Note, Figure D(B)] and Dam-dependent adenine methylation alone [Supplemental Note, Figure E(A/B), top panels]. Differential methylation analyses with respect to hemin levels were then carried out, considering signals where at least 5% mean methylation difference between the experimental conditions was observed after multiple testing correction (FDR 5%).

Dam/Dcm DNA methylation

DNA methylation signals were analyzed at 79 "GATC" motifs in the genome of P gingivalis W50, which had at least 5% mean methylation differences between hemin conditions. Of these, 36 motifs showed statistically significant differential methylation signals across hemin conditions [Table S5 (A)]. "GATC"-DMMs were located in altogether 32 genes, including a zinc-dependent metalloprotease (HMPREF1322_RS05790), a thioredoxin-disulfide reductase (HMPREF1322_RS01475), and a 4-alpha-glucanotransferase (HMPREF1322_RS03650). If genes up to ± 1 kb away from the "GATC" motifs were considered, 85 genes were candidates for possible Dam-like regulation. Sensitivity




FIG 4 Gene ontology (GO) molecular function enrichment of genes under- and over-expressed in excess hemin conditions (1.5 log2 fold change, false discovery rate = 10%). The top 30 GO molecular functions were selected to create the networks, and edges represent pathways with >10% shared genes. Darker nodes are more significantly enriched; bigger nodes represent larger gene sets; and thicker edges correspond to more overlaps between gene sets. Pathways were created based on gene matches to *P. gingivalis* W83 reference genome.

analysis at 100× coverage (66 motifs) identified 36 differentially methylated motifs as well, of which 34 were present in the main analysis [Table S5 (B)].

No minimum 5% mean methylation difference was observed at each Dcm-associated "CCWGG" motif, in line with previous observation for no overall differences in the Dcm-based PCA analysis [Supplemental Note, Figure E(A/B), bottom panels]. This suggests either the absence of enzymes targeting "CCWGG" motifs in *P. gingivalis* W50 or a minimal role of a Dcm-like response to hemin availability.

All-context 6mA/5mC DNA methylation

The proportion of differential methylation at each genomic position was analyzed for altogether 139,794 adenines and 87,398 cytosines with at least 5% mean difference in DNA methylation levels between conditions.

Forty-nine DMAs were identified between experimental conditions across the P. gingivalis W50 genome (Fig. 5). A cluster of 15 DMAs was observed in a genomic region (NZ_AJZS01000011.1 ≈12-20 kb) containing the (Fe-S)-binding protein HMPREF1322_RS00720, lactate utilization protein HMPREF1322_RS00725, hypothetical protein HMPREF1322_RS00730, Paal family thioesterase HMPREF1322_RS00735, and ABC transporter ATP-binding protein HMPREF1322_RS00740 (Fig. 5 top panel, purple; Fig. 6). In annotating DMAs to genes, if genes up to ±1 kb away from the DMA on both strands were considered, all DMAs are annotated to at least one gene for a total of 75 genes altogether. Furthermore, 25 DMAs were annotated to genes on the same strand, including seven DMAs encoding a lactate utilization protein (HMPREF1322_RS00725), five in a hypothetical protein (HMPREF1322_RS00730), and two each in a 4-alpha-glucanotransferase (HMPREF1322_RS03650) and a Ppx/GppA family phosphatase (HMPREF1322_RS06180) (Table 3). Four DMAs were located within 1 kb of a gene encoding a (Fe-S)-binding protein (HMPREF1322_RS00720). In a sensitivity analysis considering only adenines with at least 100× coverage (85,090 adenines), 20 DMAs were identified at FDR = 5% (Table S6), and all 20 were also identified in the results of the main analysis.

Forty-seven DMCs were identified between experimental conditions across the *P. gingivalis* W50 genome (Fig. 5). Two clusters of 15 and 12 DMCs emerged—the first was the same as the DMA cluster region (NZ_AJZS01000011.1, \approx 12–20 kb), and the second was in a genomic region (NZ_AJZS01000050.1, \approx 0–3.5 kb) containing the DUF2436 domain-containing protein HMPREF1322_RS04325 and nucleoside permease HMPREF1322_RS04330 (Fig. 5 bottom panel, purple and green; Fig. 6). Thirty-five DMCs were located in 16 genes




FIG 5 Differential methylation analysis results for excess hemin. Results are presented for 139,794 adenines (6mA) and 87,398 cytosines (5mC) showing a minimum 5% mean methylation difference between experimental conditions. Contigs were plotted in ascending order (NZ_AJZS01000001:104) and are delimited by the dashed lines in the graph. Genomic positions surpassing the false discovery rate = 5% significance threshold are depicted in red. Clusters of differentially methylated adenine sites (DMAs) and differentially methylated cytosines (DMCs) are highlighted in purple and green. The DMA/DMC cluster highlighted in purple is shown in detail in Fig. 6.

including in genes identified in the DMA analyses above. Specifically, four DMCs were located in genes encoding the (Fe-S)-binding protein HMPREF1322_RS00720, two in the lactate utilization protein HMPREF1322_RS00725, and two in the hypothetical protein HMPREF1322_RS00730 reported above for 6mA. Single DMCs were also identified in the 4-alpha-glucanotransferase HMPREF1322_RS03650 and Ppx/GppA family phosphatase HMPREF1322_RS06180 genes (Table 4). Overall, if genes up to ±1 kb away on both strands were considered, 31 genes harbored DMCs, of which 10 also harbored DMAs. Other genes annotated to the DMCs identified included those encoding transporter proteins such as an iron ABC transporter permease (HMPREF1322_RS01240) and others (HMPREF1322_RS01245; HMPREF1322_RS06460). In sensitivity analysis considering only cytosines with at least 100× coverage (46,930 cytosines), 47 DMCs were also identified, of which 27 were also in the main analysis results (Table S7).

We explored evidence for putative DNA sequence motifs at the identified all-context DMAs and DMCs. First, we observed that the DMAs identified in this all-context analysis (Table 3) did not overlap with our "GATC"-DMM results (Table S5). We observed, however, that the 4-alpha-glucanotransferase HMPREF1322_RS03650 and the DUF3298 domain-containing protein HMPREF1322_RS07770 contained respectively two and one DMAs within 500 bp of a "GATC"-DMM. Overall, DMAs and "GATC"-DMMs shared 13 genes annotated within 1 kb of their location (out of 75 and 85 genes respectively identified for DMAs and "GATC"-DMMs) (Table S5). Second, we searched for over-representation of up to 15-nucleotide long sequences surrounding all DMAs and DMCs. Although the analyses identified putative sequences of length 10–11 nucleotides, the results did not reach statistical significance (MEME E-value >0.05; Supplemental Note, Figure F).




FIG 6 Genomic cluster of differential expression, adenine, and cytosine methylation in the lactate utilization protein (HMPREF1322_RS00725) gene locus. (A) DNA methylation patterns in the locus. Adenine (circles) and cytosine (triangles) percentage of methylation in this gene locus are shown in limited (LiH; red) and excess (ExH; blue) hemin conditions. Differentially methylated adenine sites (DMAs) and differentially methylated cytosines (DMCs) (larger data points) were observed within a 100 bp or 1000 bp window from the gene and a generalized additive model curve was fitted to the methylation values. (B) Differential expression and methylation in the lactate gene cluster. The lactate utilization protein HMPREF1322_RS00725 was located in a cluster of genes conserved between *P. gingivalis* W50 and reference strain W83. Genes in this location were affected by both DNA methylation (DMA/DMC, green/yellow) and gene expression (differentially expressed genes, orange) changes. (C and D) Differential adenine (C) and cytosine (D) methylation was statistically significant upstream (–100 bp), downstream (+100 bp), and in the gene body of HMPREF1322_RS00725 using the Wilcoxon signed-ranked test. (E) Increased methylation in ExH was accompanied by decreased gene expression of HMPREF1322_RS00725.

Genes with coordinated differential DNA methylation and expression changes

We assessed whether the observed DEGs also exhibited DNA methylation changes for 6mA and 5mC. We first compared DEGs to DMAs and DMCs each (Fig. 7), and then explored further genomic regions that contained DEGs, DMAs, and DMCs (Fig. 7).

Overall, 23 DEGs also harbored DMAs (Table 5 and 6). Of these, eight genes were over-expressed in excess hemin including the SDR family oxidoreductase HMPREF1322_RS07305 (*P. gingivalis* W83: PG2069) and the Ppx/GppA family phosphatase HMPREF1322_RS06180 (*P. gingivalis* W83: PG1739) genes (Table 5). In all the eight cases, the DMA was on the same strand as the gene, located either in or upstream of the gene (Table 5), with hypermethylation in excess hemin for most

mSystems

TABLE 3 Differentially methylated adenine sites (6mA) identified in *P. gingivalis* W50, selecting for a minimum mean 5% methylation difference between experimental conditions (false discovery rate = 5% and minimum 10× coverage)°

							: !				
Contig	Position	Strand		Mean %	% methyla-	<i>P</i> -value	Gene ID (locus tag)	Gene	Gene product	Gene on	Genes ± 1 kb away, both
			methylation: LiH	methylation:	tion			symbol		the same	strands
				EXH	difference					strand	
NZ_AJZS01000047.1	40035	1	71.83%	77.08%	5.25%	7.49E-08	HMPREF1322_RS0425	thrS	Threonine—tRNA ligase	No	HMPREF1322_RS04255
NZ A17501000038 1	3559	I	443%	89 64%	85 21%	7,67F-08	5 HMPRFF1322_RS0365	I	4-Alpha-clucapotransferase	Yes	HMPRFF1322 RS03645 HMP
							0				REF1322_RS03650
NZ_AJZS01000050.1	55602	+	53.36%	63.37%	10.01%	1.98E-07	HMPREF1322_RS0453	I	Aminopeptidase	No	HMPREF1322_RS04535,HMP
							5				REF1322_RS10055
NZ_AJZS01000066.1	22242	ı	15.95%	%08'96	%98.08	3.66E-07	HMPREF1322_RS0618	I	Ppx/GppA family	Yes	HMPREF1322_RS06175,HMP
							0		phosphatase		REF1322_RS06180
NZ_AJZS01000011.1	13584	+	2.40%	14.66%	12.25%	5.18E-07	HMPREF1322_RS0072	I	Lactate utilization protein	Yes	HMPREF1322_RS00720,HMP
							2				REF1322_RS00725,
											HMPREF1322_RS00730
NZ_AJZS01000009.1	24820	I	0.00%	6.32%	6.32%	1.07E-06	HMPREF1322_RS0064	pckA	Phosphoenolpyruvate	No	HMPREF1322_RS00645,HMP
							2		carboxykinase (ATP)		REF1322_RS00650,
											HMPREF1322_RS00655
NZ_AJZS01000097.1	917	+	6.32%	0.00%	6.32%	1.07E-06	HMPREF1322_RS0902	I	Lipid A deacylase	No	HMPREF1322_RS09015,HMP
							0				REF1322_RS09020,
											HMPREF1322_RS09025
NZ_AJZS01000099.1	2869	I	55.68%	47.10%	8.58%	1.41E-06	1	ı	1	I	HMPREF1322_RS09365,HMP
											REF1322_RS09370,
											HMPREF1322_RS09375
NZ_AJZS01000011.1	14744	+	2.00%	28.52%	26.52%	1.52E-06	HMPREF1322_RS0073	I	Hypothetical protein	Yes	HMPREF1322_RS00725,HMP
							0				REF1322_RS00730,
											HMPREF1322_RS00735
NZ_AJZS01000020.1	1186	+	6.83%	%00.0	6.83%	1.66E-06	HMPREF1322_RS0192	ı	Histidinol-phosphate	Yes	HMPREF1322_RS01920,HMP
							5		aminotransferase		REF1322_RS09820,
											HMPREF1322_RS01925
NZ_AJZS01000048.1	2988	1	0.00%	8.01%	8.01%	1.70E-06	HMPREF1322_RS1067	I	Hypothetical protein	No	HMPREF1322_RS04285,HMP
							5				REF1322_RS10675,
											HMPREF1322_RS04295
NZ_AJZS01000011.1	14487	+	0.97%	19.32%	18.35%	2.62E-06	HMPREF1322_RS0073	I	Hypothetical protein	Yes	HMPREF1322_RS00725,HMP
							0				REF1322_RS00730,
											HMPREF1322_RS00735
NZ_AJZS01000091.1	1018	I	16.24%	%00.0	16.24%	2.94E-06	HMPREF1322_RS0851	I	8-Amino-7-oxono-noate	No	HMPREF1322_RS08515
							5		synthase		
											(Continued on next page)

Downloaded from https://journals.asm.org/journal/msystems on 26 January 2024 by 2.126.43.57.

 ${\sf mSystems}$

TABLE 3 Differentially methylated adenine sites (6mA) identified in *P. gingivalis* W50, selecting for a minimum mean 5% methylation difference between experimental conditions (false discovery rate = 5% and minimum 10× coverage) (Continued)

2:4:0	Docition	Cenand	Man 0/	Mose 0/	olyndram /0	onless of	(2000) (1000)	0,00	40.1000	3000	4404
S S S S S S S S S S S S S S S S S S S	1031601			Wedii 70	-o illetiiyid-	r value		. פּוֹב	delle product	משונים ה	Gelles - I no away, bottl
			methylation: LiH	methylation:	tion			symbol		the same	strands
				ExH	difference					strand	
NZ_AJZS01000011.1	14511	+	4.96%	46.35%	41.39%	3.60E-06	HMPREF1322_RS0073	I	Hypothetical protein	Yes	HMPREF1322_RS00725,HMP
							0				REF1322_RS00730,
											HMPREF1322_RS00735
NZ_AJZS01000011.1	14324	+	1.76%	17.10%	15.34%	3.75E-06	HMPREF1322_RS0072	ı	Lactate utilization protein	Yes	HMPREF1322_RS00725,HMP
							2				REF1322_RS00730,
											HMPREF1322_RS00735
NZ_AJZS01000067.1	34053	I	34.85%	21.64%	13.21%	4.13E-06	HMPREF1322_RS0641	porQ	Type IX secretion system	Yes	HMPREF1322_RS06405,HMP
							2		protein PorQ		REF1322_RS06410,
											HMPREF1322_RS06415
NZ_AJZS01000011.1	13965	+	3.83%	37.85%	34.02%	4.16E-06	HMPREF1322_RS0072	ı	Lactate utilization protein	Yes	HMPREF1322_RS00720,HMP
							2				REF1322_RS00725,
											HMPREF1322_RS00730
NZ_AJZS01000011.1	14644	+	5.20%	29.07%	23.87%	4.28E-06	HMPREF1322_RS0073	ı	Hypothetical protein	Yes	HMPREF1322_RS00725,HMP
							0				REF1322_RS00730,
											HMPREF1322_RS00735
NZ_AJZS01000066.1	22938	I	85.99%	37.41%	48.59%	4.56E-06	HMPREF1322_RS0618	ı	Ppx/GppA family	Yes	HMPREF1322_RS06175,HMP
							0		phosphatase		REF1322_RS06180,
											HMPREF1322_RS06185
NZ_AJZS01000038.1	3560	I	1.45%	86.22%	84.77%	5.31E-06	HMPREF1322_RS0365	ı	4-Alpha-glucanotransferase	Yes	HMPREF1322_RS03645,HMP
							0				REF1322_RS03650
NZ_AJZS01000011.1	13236	+	6.84%	52.42%	45.58%	5.83E-06	HMPREF1322_RS0072	I	Lactate utilization protein	Yes	HMPREF1322_RS00720,HMP
							5				REF1322_RS00725
NZ_AJZS01000071.1	5863	1	62.88%	80.42%	17.54%	6.37E-06	HMPREF1322_RS0730	ı	SDR family oxidoreductase	Yes	HMPREF1322_RS07300,HMP
							5				REF1322_RS07305,
											HMPREF1322_RS07310,HMP
											REF1322_RS07315
NZ_AJZS01000029.1	4423	1	5.57%	%00.0	5.57%	6.37E-06	HMPREF1322_RS0307	ı	AAA domain-containing	Yes	HMPREF1322_RS03070,HMP
							5		protein		REF1322_RS03075
NZ_AJZS01000046.1	4018	1	3.69%	15.60%	11.90%	6.52E-06	HMPREF1322_RS0410	ı	Hypothetical protein	Yes	HMPREF1322_RS04100,HMP
							0				REF1322_RS10660
NZ_AJZS01000069.1	36533	ı	13.51%	18.84%	5.33%	6.81E-06	HMPREF1322_RS0661	I	ComEC/Rec2 family	No	HMPREF1322_RS06605,HMP
							0		competence protein		REF1322_RS06610
NZ_AJZS01000093.1	1666	I	34.44%	16.94%	17.50%	8.21E-06	HMPREF1322_RS0868	pruA	L-glutamate gamma-semial-	Yes	HMPREF1322_RS08685,HMP
							2		dehyde dehydrogenase		REF1322_RS08690
											(Continued on next page)

Downloaded from https://journals.asm.org/journal/msystems on 26 January 2024 by 2.126.43.57.

TABLE 3 Differentially methylated adenine sites (6mA) identified in *P. gingivalis* W50, selecting for a minimum mean 5% methylation difference between experimental conditions (false discovery rate = 5% and minimum 10× coverage) (Continued)

Contia	Position	Strand	Mean %	Mean %	% methyla-	A-value	Gene ID (locus tad)	Gene	Gene product	Geneon	Gene on Genes + 1 kh away both
			플	methylation:	tion			symbol		the same strands	strands
				ExH	difference					strand	
NZ_AJZS01000011.1	14200	+	5.92%	18.54%	12.62%	8.66E-06	HMPREF1322_RS0072	ı	Lactate utilization protein	Yes	HMPREF1322_RS00725,HMP
							5				REF1322_RS00730,
											HMPREF1322_RS00735
NZ_AJZS01000063.1	3841	I	5.37%	%00.0	5.37%	8.67E-06	ı	I	I	I	HMPREF1322_RS05995
NZ_AJZS01000101.1	9445	I	20.00%	75.93%	25.93%	9.71E-06	I	I	I	I	HMPREF1322_RS09650,HMP
											REF1322_RS09490,
											HMPREF1322_RS09495
NZ_AJZS01000091.1	663	I	5.19%	%00.0	5.19%	9.98E-06	HMPREF1322_RS0851	I	8-Amino-7-oxono-noate	No	HMPREF1322_RS08515
							5		synthase		
NZ_AJZS01000068.1	5296	I	24.60%	41.90%	17.30%	1.10E-05	HMPREF1322_RS0644	I	GlycinetRNA-ligase	Yes	HMPREF1322_RS06440,HMP
							0				REF1322_RS06445
NZ_AJZS01000011.1	15471	+	7.97%	28.75%	20.78%	1.11E-05	HMPREF1322_RS0073	I	Paal family thioesterase	No	HMPREF1322_RS00725,HMP
							5				REF1322_RS00730,
											HMPREF1322_RS00735,HMP
											REF1322_RS00740
NZ_AJZS01000085.1	7204	I	33.33%	29.05%	25.72%	1.12E-05	HMPREF1322_RS0815	I	M56 family metallopepti-	No	HMPREF1322_RS08150,HMP
							5		dase		REF1322_RS08155,
											HMPREF1322_RS10845
NZ_AJZS01000069.1	173248	ı	37.82%	19.39%	18.43%	1.14E-05	HMPREF1322_RS0725	I	Site-specific integrase	No	HMPREF1322_RS07245,HMP
							0				REF1322_RS07250,
											HMPREF1322_RS07255
NZ_AJZS01000011.1	19392	+	7.54%	25.19%	17.66%	1.14E-05	HMPREF1322_RS0074	I	ABC transporter ATP-	No	HMPREF1322_RS00745
							5		binding protein		
NZ_AJZS01000048.1	4837	I	%00:0	9.05%	9.05%	1.15E-05	ı	I	ı	I	HMPREF1322_RS04280,HMP
											REF1322_RS04285
NZ_AJZS01000011.1	17614	+	2.76%	16.42%	13.66%	1.15E-05	HMPREF1322_RS0074	I	ABC transporter ATP-	No	HMPREF1322_RS00740,HMP
							0		binding protein		REF1322_RS00745
NZ_AJZS01000046.1	4605	I	%69.9	%00.0	%69.9	1.30E-05	HMPREF1322_RS1066	I	ISAs1 family transposase	Yes	HMPREF1322_RS04100,HMP
							0				REF1322_RS10660
NZ_AJZS01000001.1	12773	+	28.09%	33.33%	24.76%	1.31E-05	HMPREF1322_RS0005	I	Tryptophanase	Yes	HMPREF1322_RS00055
							2				
NZ_AJZS01000025.1	6136	+	20.06%	%00.0	20.06%	1.32E-05	HMPREF1322_RS0231	I	Tetratricopeptide repeat	N _o	HMPREF1322_RS02310,HMP
							2		protein		REF1322_RS02315
NZ_AJZS01000050.1	2012	I	39.24%	1.99%	37.26%	1.46E-05	1	I	1	I	HMPREF1322_RS04325,HMP
											REF1322_RS04330
											(Continued on next page)

Downloaded from https://journals.asm.org/journal/msystems on 26 January 2024 by 2.126.43.57.

TABLE 3 Differentially methylated adenine sites (6mA) identified in *P. gingivalis* W50, selecting for a minimum mean 5% methylation difference between experimental conditions (false discovery rate = 5% and minimum 10× coverage) (Continued)

Contig	Position	Strand	Mean %	Mean %	% methyla-	P-value	Gene ID (locus tag)	Gene	Gene Gene product	Gene on	Gene on Genes ± 1 kb away, both
			methylation: LiH	methylation:	tion			symbol		the same	the same strands
				EXH	difference					strand	
NZ_AJZS01000050.1	1015	+	0.00%	16.57%	16.57%	1.47E-05	HMPREF1322_RS0432	ı	DUF2436 domain-contain-	N _o	HMPREF1322_RS04325
							5		ing protein		
NZ_AJZS01000011.1	14019	+	1.48%	34.21%	32.73%	1.48E-05	HMPREF1322_RS0072	ı	Lactate utilization protein	Yes	HMPREF1322_RS00720,HMP
							2				REF1322_RS00725,
											HMPREF1322_RS00730
NZ_AJZS01000079.1	3864	I	76.11%	60.84%	15.27%	1.52E-05	HMPREF1322_RS0777	I	DUF3298 domain-contain-	Š	HMPREF1322_RS07770,HMP
							0		ing protein		REF1322_RS07775,
											HMPREF1322_RS07780
NZ_AJZS01000011.1	14512	+	5.03%	41.65%	36.62%	1.56E-05	HMPREF1322_RS0073	I	Hypothetical protein	Yes	HMPREF1322_RS00725,HMP
							0				REF1322_RS00730,
											HMPREF1322_RS00735
NZ_AJZS01000007.1	2872	ı	16.32%	6.02%	10.30%	1.62E-05	I	I	I	I	HMPREF1322_RS00445,HMP
											REF1322_RS00450
NZ_AJZS01000011.1	14323	+	2.43%	19.81%	17.38%	1.65E-05	HMPREF1322_RS0072	I	Lactate utilization protein	Yes	HMPREF1322_RS00725,HMP
							5				REF1322_RS00730,
											HMPREF1322_RS00735
NZ_AJZS01000017.1	23369	1	13.67%	18.77%	5.10%	1.66E-05	I	I	I	I	HMPREF1322_RS01475,HMP
											REF1322_RS01480,
											HMPREF1322_RS01485,HMP
											REF1322_RS01490
NZ_AJZS01000021.1	7225	+	11.70%	17.64%	5.94%	1.67E-05	HMPREF1322_RS0197	I	O-acetyl-ADP-ribose	No	HMPREF1322_RS01970,HMP
							5		deacetylase		REF1322_RS01975,
											HMPREF1322_RS01980

^aLiH, growth in limited hemin; ExH, growth in excess hemin.

TABLE 4 Differentially methylated cytosines (5mC) identified in *P. gingivalis* W50, selecting for a minimum mean 5% methylation difference between experimental conditions (false discovery rate = 5% and minimum 10×coverage)^a

March Delian Marc	Contig	Position Strand	Strand	Mean %	Mean %	% methylation	P-value	Gene ID (locus tag)	Gene symbo	Gene symbol Gene product	Gene on th	Gene on the Genes ± 1 kb away, both strands
14 12 12 12 13 14 14 15 13 14 14 14 15 14 14 14 15 14 14	•											
1,140 1,141 1,14					methylation:	difference				S	same strar	pt.
580 - 6.07% 1127% 5.04% 3.196.71 HWHEFT 322, 15000333 - Pyralidas dependent annionanders Yes HWHEFT 322, 1500033 1410 - 5.53% 5.23% 6.03% 4.166.71 HWHEFT 322, 1500033 - 4.40m-syllamorbanders Yes HWHEFT 322, 1500033 1410 - 1.677% 4.73% 3.02% 7.466.71 HWHEFT 322, 1500033 - 4.40m-syllamorbanders Yes HWHEFT 322, 1500033 101 - 2.65% 8.25% 7.45% 1.326.64 HWHEFT 322, 1500033 - Lacate defination protein Yes HWHEFT 322, 1500033 113.00 - 2.45% 8.75% 1.51% 1.06.60 HWHEFT 322, 1500033 - Lacate defination protein Yes HWHEFT 322, 1500033 113.00 - 2.45% 3.17% 1.016.05 HWHEFT 322, 1500033 - Lacate defination protein Yes HWHEFT 322, 1500033 113.00 - 2.45% 1.01% HWHEFT 322, 1500033 - Lacate defination protein </th <th></th> <th></th> <th></th> <th>플</th> <th>EXH</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th>				플	EXH							
14156 1 1677% 47.3 cm 14.0	NZ_AJZS01000102.1	6840	ı	6.63%	12.27%	5.64%	3.39E-07	HMPREF1322_RS09535	ı	Pyridoxal phosphate-dependent aminotransfer-	Yes	HMPREF1322_RS09535,HMPREF1322_RS09540
3538 - 1 52.38 68.09% 4.16.67 HAMPET 122, 560325 - Adjoin-sphiotoministenes 10 HAMPET 122, 560372 - Adjoin-sphiotoministenes 10 HAMPET 1										ase		
11.10 1. 1. 1. 1. 1. 1.	NZ_AJZS01000038.1	3558	ı	5.53%	95.22%	89.69%	4.16E-07	HMPREF1322_RS03650	ı	4-Alpha-glucanotransferase	Yes	HMPREF1322_RS03645,HMPREF1322_RS03650
14.10 1. 1. 1. 1. 1. 1. 1.	NZ_AJZS01000066.1	22243	ı	10.21%	64.13%	53.91%	6.11E-07	HMPREF1322_RS06180	ı	Ppx/GppA family phosphatase	Yes	HMPREF1322_RS06175,HMPREF1322_RS06180
13-20 1- 34-56% 23-26% 23-26% 23-26% 1-6-20	NZ_AJZS01000011.1	14106	+	16.77%	47.36%	30.59%	7.45E-07	HMPREF1322_RS00725	ı	Lactate utilization protein	Yes	HMPREF1322_RS00720,HMPREF1322_RS00725,
1011 4 66.51% 52.49% 7.42% 1.326.06 HHMFEH 1222, S600221 - 5 Shenhy pepcidishe Yes HHMFEH 1222, S600221 - 5 Shenhy pepcidishe Yes HHMFEH 1222, S600221 - Chick HHMFEH 1222, S600221 - - HHMFEH 1222, S600221 - HHMFEH 1222, S600221 - HHMFEH 1222, S600221 - HHMFEH 1222, S600221 HHMFEH 1222, S600221 - HHMFEH 1222, S600221 HHMFEH 1222, S600222 HHMFE												HMPREF1322_RS00730
1374 4 87.9% 82.9% 82.9% 137.5% 1375.0 144PRET 132, 1850273 5 144PRET 132, 1850273	NZ_AJZS01000047.1	30511	+	65.91%	58.49%	7.42%	1.42E-06	HMPREF1322_RS04210	ı	S9 family peptidase	Yes	HMPREF1322_RS04205,HMPREF1322_RS04210
13174 + 1 670% 4 1387% 3512% 1512, 611E-06 HIMPRET 1322, 8500073 - 1 Gate utilization protein	NZ_AJZS01000050.1	1612	ı	34.96%	8.22%	26.74%	1.53E-06	HMPREF1322_RS04325	ı	DUF2436 domain-containing protein	Yes	HMPREF1322_RS04325,HMPREF1322_RS04330
1374 1, 1778 1, 1788 1, 1789	NZ_AJZS01000011.1	13240	+	8.76%	43.87%	35.12%	1.61E-06	HMPREF1322_RS00725	ı	Lactate utilization protein	Yes	HMPREF1322_RS00720,HMPREF1322_RS00725
1378 4 3476% 6.016% 5.24E.0 HMREF1322,RS00725 9. Actave utilization ponein 1.56 HMREF1322,RS00725 1.25 1	NZ_AJZS01000011.1	12946	+	4.71%	58.08%	53.37%	2.09E-06	HMPREF1322_RS00720	ı	(Fe-S)-binding protein	Yes	HMPREF1322_RS00715,HMPREF1322_RS00720,
1376 1												HMPREF1322_RS00725
5938 4 34,76% 52,53% 17,87% 24,56 IMPREF1322_RS0036 PLG Molecular chaperone HtpG No IMPREF1322_RS0036 1569 4 513,3% 2,15% 51,03% 2,046.6 IMPREF1322_RS0032 2 Def-3436 domah-containing protein Yes IMPREF1322_RS0036 15246 4 5,15% 5,15% 2,716.0 IMPREF1322_RS0032 2 Def-3436 domah-containing protein Yes IMPREF1322_RS0032 1307 4 3,76% 5,15% 3,176.0 IMPREF1322_RS0032 2 Gebinding protein Yes IMPREF1322_RS0032 1307 4 2,15% 3,15% 3,15% 1,17% 4,14% IMPREF1322_RS0032 2 Gebinding protein Yes IMPREF1322_RS0032 1307 4 4,25% 1,13% 4,48E-0 IMPREF1322_RS0032 2 Gebinding protein Yes IMPREF1322_RS0032 1504 4 6,15% 3,15% 4,48E-0 IMPREF1322_RS0032 2 Gebinding protein Yes IMPREF1322_	NZ_AJZS01000011.1	13178	+	7.08%	60.16%	53.08%	2.24E-06	HMPREF1322_RS00725	ı	Lactate utilization protein	Yes	HMPREF1322_RS00720,HMPREF1322_RS00725
1304 4 51.8% 6 17.9% 56.6% 5.08% 5.06% 1.09% 2.06% 1.09% 1.09% 2.06% 1.09%	NZ_AJZS01000014.1	5938	+	34.76%	52.63%	17.87%	2.45E-06	HMPREF1322_RS00860	htpG	Molecular chaperone HtpG	No	HMPREF1322_RS00860
13834 + 5,18% 61,79% 5,661% 2,71E-06 HMPREF1322_RS0072 - (re-3)-binding protein Yes HMPREF1322_RS0072 8834 - 0.00% 53,38% 51,62% 3,17E-06 HMPREF1322_RS0072 - (re-3)-binding protein Yes HMPREF1322_RS0072 1302 + 4,20% 51,62% 3,65E-06 HMPREF1322_RS0072 - (re-3)-binding protein Yes HMPREF1322_RS0072 305 + 4,10% 11,13% 20,13% 4,42E-06 HMPREF1322_RS0072 - (re-3)-binding protein Yes HMPREF1322_RS0072 305 + 4,00% 11,13% 20,13% 4,42E-06 HMPREF1322_RS0072 - 1-4-binding protein Yes HMPREF1322_RS0072 205 + 1,113% 20,13% 4,32E-06 HMPREF1322_RS0032 - 1-4-binding protein Yes HMPREF1322_RS0032 205 + 2,52% 4,40% 6,00E-06 HMPREF1322_RS0032 - 1-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4-4	NZ_AJZS01000050.1	1569	ı	53.78%	2.75%	51.03%	2.69E-06	HMPREF1322_RS04325	ı	DUF2436 domain-containing protein	Yes	HMPREF1322_RS04325,HMPREF1322_RS04330
8834 – 0.00% 7.90% 3.17E-06 HMPREFI 322_RSO961 – Tetratricopeptide repeat protein Yes HMPREFI 322_RSO971 13002 + 3.7%% 55.38% 3.17E-06 HMPREFI 322_RSO962 - (Fe-5)-binding protein Yes HMPREFI 322_RSO972 13002 + 4.20% 51.69% 17.79% 4.42E-06 HMPREFI 322_RSO972 - (Fe-5)-binding protein Yes HMPREFI 322_RSO973 305 + 6.19% 17.79% 4.42E-06 HMPREFI 322_RSO923 - - - - HMPREFI 322_RSO936 2009 - 6.19% 17.79% 4.42E-06 HMPREFI 322_RSO938 -	NZ_AJZS01000011.1	12945	+	5.18%	61.79%	56.61%	2.71E-06	HMPREF1322_RS00720	ı	(Fe-S)-binding protein	Yes	HMPREF1322_RS00715,HMPREF1322_RS00720,
8834 - 0.00% 7.90% 7.90% 3.17-6.6 HMPREF1322_RSO950 - Citation protein Yes HMPREF1322_RSO972 13002 + 3.76% 55.38% 51.62% 3.66% HMPREF1322_RSO972 - Tetraticopeptide epeat protein Yes HMPREF1322_RSO972 1307 + 4.20% 51.99% 4.88E-0 HMPREF1322_RSO972 - Tetraticopeptide protein Yes HMPREF1322_RSO973 205 - 17.19% 4.88E-0 HMPREF1322_RSO923 - DUF2436 domain-containing protein Yes HMPREF1322_RSO932 205 - 26.10% 4.88E-0 HMPREF1322_RSO933 - DUF2436 domain-containing protein Yes HMPREF1322_RSO933 205 - 1.13.70% 6.03% 6.03% HMPREF1322_RSO933 - DUF2436 domain-containing protein Yes HMPREF1322_RSO933 4144 - 6.03% 6.03% HMPREF1322_RSO933 - CusACccA family heavy metal efflux RND Yes HMPREF1322_RSO933 1444 - </td <td></td> <td>HMPREF1322_RS00725</td>												HMPREF1322_RS00725
1302 4 37.9% 55.3% 51.62% 3.62% 4.48E-0 4.4MPREFI 322_R500720 -	NZ_AJZS01000104.1	8834	ı	0.00%	7.90%	7.90%	3.17E-06	HMPREF1322_RS09610	ı	Tetratricopeptide repeat protein	Yes	HMPREF1322_RS09605,HMPREF1322_RS09610
1307 + 4.20% 21.99% 17.79% 4.48E-6 HMPREF1322_RS00720 -	NZ_AJZS01000011.1	13002	+	3.76%	55.38%	51.62%	3.63E-06	HMPREF1322_RS00720	ı	(Fe-S)-binding protein	Yes	HMPREF1322_RS00715,HMPREF1322_RS00720,
1307 + 4.20% 17.79% 4.48E-66 HMPREFI 322_RS00726 - (Fe-S)-binding protein Yes HMPREFI 322_RS00365 305 + 6.19% 17.19% 10.99% 4.82E-66 HMPREFI 322_RS00365 - C-2-binding protein Yes HMPREFI 322_RS00365 1624 - 31.26% 11.13% 20.13% 5.57E-66 HMPREFI 322_RS00365 - DUF436 domain-containing protein Yes HMPREFI 322_RS0366 2099 - 58.19% 6.08% 6.02E-66 HMPREFI 322_RS0368 - CusACACA family heavy metal efflux RND No HMPREFI 322_RS0386 1920 - 6.472% 8.33% 6.03E-66 HMPREFI 322_RS0388 - U.32 family peptidase No HMPREFI 322_RS0388 1920 - 6.472% 8.33% 6.03E-66 HMPREFI 322_RS0388 - U.32 family peptidase No HMPREFI 322_RS0388 1920 - 6.472% 8.33% 6.03E-66 HMPREFI 322_RS03886 - U.32 family peptidase No HMPREFI 322_R												HMPREF1322_RS00725
365 + 6.19% 17.19% 10.99% 48.2E-06 - <td>NZ_AJZS01000011.1</td> <td>13071</td> <td>+</td> <td>4.20%</td> <td>21.99%</td> <td>17.79%</td> <td>4.48E-06</td> <td>HMPREF1322_RS00720</td> <td>ı</td> <td>(Fe-S)-binding protein</td> <td>Yes</td> <td>HMPREF1322_RS00720,HMPREF1322_RS00725</td>	NZ_AJZS01000011.1	13071	+	4.20%	21.99%	17.79%	4.48E-06	HMPREF1322_RS00720	ı	(Fe-S)-binding protein	Yes	HMPREF1322_RS00720,HMPREF1322_RS00725
1624 - 31.26% 11.13% 5.57E-06 IMPREF1322_RS04326 - DUE2436 domain-containing protein Yes HMPREF1322_RS04328 2099 - 58.19% 8.09% 50.10% 6.02E-06 IMPREF1322_RS04336 - DUE2436 domain-containing protein Yes HMPREF1322_RS04328 41404 - 6.240% 6.08% 6.02E-06 IMPREF1322_RS04386 - CLSA/CZAC family heavy metal efflux RND No IMPREF1322_RS04328 952 + 13.70% 6.08% 6.03E-06 IMPREF1322_RS00486 - CLSA/CZAC family heavy metal efflux RND No IMPREF1322_RS04328 1920 - 6.472% 8.39% 6.03E-06 IMPREF1322_RS00486 - U32 family peptidase No IMPREF1322_RS04328 1940 - 16.78% 7.96E-06 IMPREF1322_RS00730 - Hypothetical protein Yes IMPREF1322_RS04328 1044 - 16.78% 5.25% 8.29E-06 IMPREF1322_RS04309 - Hypothetical protein Yes IMPREF1322_RS04328	NZ_AJZS01000039.1	305	+	6.19%	17.19%	10.99%	4.82E-06	ı	ı	ı	ı	HMPREF1322_RS03655
2099 - 58.19% 6.00% 6.01% 6.00E-06 HMPREFI 322_RS0358S - Nucleoside permease Yes HMPREFI 322_RS0358S 41404 - 62.40% 68.48% 6.02E-06 HMPREFI 322_RS0358S - CusACZcA family heavy metal efflux RND No HMPREFI 322_RS0358S 952 + 13.70% 22.02% 8.33% 6.03E-06 HMPREFI 322_RS008SS - U32 family peptidase No HMPREFI 322_RS003SS 1920 - 64.72% 8.33% 56.32% 7.20E-06 HMPREFI 322_RS003SS - U32 family peptidase No HMPREFI 322_RS003SS 1459 + 26.82% 7.20E-06 HMPREFI 322_RS007SS - HMPREFI 322_RS007SS - HMPREFI 322_RS007SS 14542 + 15.67% 5.27% 8.29E-06 HMPREFI 322_RS007SS - Hyporthetical protein Yes HMPREFI 322_RS007SS 4471 - 17.52% 5.41% 9.62E-06 HMPREFI 322_RS043SS - Hyporthetical protein Yes HMPREFI 322_RS032SS </td <td>NZ_AJZS01000050.1</td> <td>1624</td> <td>ı</td> <td>31.26%</td> <td>11.13%</td> <td>20.13%</td> <td>5.57E-06</td> <td>HMPREF1322_RS04325</td> <td>ı</td> <td>DUF2436 domain-containing protein</td> <td>Yes</td> <td>HMPREF1322_RS04325,HMPREF1322_RS04330</td>	NZ_AJZS01000050.1	1624	ı	31.26%	11.13%	20.13%	5.57E-06	HMPREF1322_RS04325	ı	DUF2436 domain-containing protein	Yes	HMPREF1322_RS04325,HMPREF1322_RS04330
41404 - 62.40% 6.08% 6.02E-06 IMPREFI 322_RS03858 - CLAA/CACA family heavy metal efflux RND No IMPREFI 322_RS03858 952 + 13.70% 22.02% 8.33% 6.03E-06 IMPREFI 322_RS00885 - U32 family peptidase No IMPREFI 322_RS00328 1920 - 64.72% 8.33% 7.23E-06 IMPREFI 322_RS00885 - U32 family peptidase No IMPREFI 322_RS00328 14698 + 26.82% 44.78% 7.29E-06 IMPREFI 322_RS0039 - Hypothetical protein Yes IMPREFI 322_RS0073 14592 + 15.67% 5.27% 8.29E-06 IMPREFI 322_RS00730 - Hypothetical protein Yes IMPREFI 322_RS00731 4471 - 17.52% 5.41% 9.62E-06 IMPREFI 322_RS00730 - Hypothetical protein Yes IMPREFI 322_RS03866 4471 - 17.52% 5.41% 9.62E-06 IMPREFI 322_RS04325 - Hypothetical protein Yes IMPREFI 322_RS038686 <tr< td=""><td>NZ_AJZS01000050.1</td><td>2099</td><td>ı</td><td>58.19%</td><td>8.09%</td><td>50.10%</td><td>6.00E-06</td><td>HMPREF1322_RS04330</td><td>ı</td><td>Nucleoside permease</td><td>Yes</td><td>HMPREF1322_RS04325,HMPREF1322_RS04330</td></tr<>	NZ_AJZS01000050.1	2099	ı	58.19%	8.09%	50.10%	6.00E-06	HMPREF1322_RS04330	ı	Nucleoside permease	Yes	HMPREF1322_RS04325,HMPREF1322_RS04330
952 + 13.70% 22.02% 8.33% 6.03E-06 HMPREF1322_RS00885 - U32 family peptidase No HMPREF1322_RS00882 1920 - 64.72% 8.39% 56.32% 7.23E-06 - HMPREF1322_RS00739 - - HMPREF1322_RS00732 14698 + 26.82% 47.78% 17.96% 7.90E-06 HMPREF1322_RS00730 - Hypothetical protein Yes HMPREF1322_RS00731 1044 - 10.78% 5.52% 8.29E-06 HMPREF1322_RS00730 - Hypothetical protein Yes HMPREF1322_RS00731 4471 - 15.67% 34.20% 18.53% 8.76E-06 HMPREF1322_RS00730 - Hypothetical protein Yes HMPREF1322_RS00731 4471 - 17.52% 5.41% 9.62E-06 HMPREF1322_RS00432 - Hypothetical protein Yes HMPREF1322_RS00433 1625 - 16.28% 16.48% 9.79E-06 HMPREF1322_RS004325 - DUIF2436 domain-containing protein Yes HMPRE	NZ_AJZS01000037.1	41404	ı	62.40%	68.48%	%80.9	6.02E-06	HMPREF1322_RS03585	ı	CusA/CzcA family heavy metal efflux RND	8	HMPREF1322_RS03585,HMPREF1322_RS03590
952 + 13.70% 2.02% 8.33% 6.03E-06 HMPREFI322_RS00885 - U32 family peptidase No HMPREFI322_RS00882 1920 - 64.72% 8.39% 56.32% 7.23E-06 - - - - - - HMPREFI322_RS00732 14698 + 26.82% 44.78% 17.96% 7.90E-06 HMPREFI322_RS00730 - Hypothetical protein Yes HMPREFI322_RS00732 1044 - 10.78% 5.52% 8.29E-06 HMPREFI322_RS00730 - Hypothetical protein Yes HMPREFI322_RS00733 4471 - 15.67% 34.20% 8.76E-06 HMPREFI322_RS00730 - Hypothetical protein Yes HMPREFI322_RS00733 4471 - 17.52% 5.41% 9.62E-06 HMPREFI322_RS00432 - - - - HMPREFI322_RS00433 1625 - 16.48% 9.79E-06 HMPREFI322_RS004325 - - - - - - -										transporter		
1920 - 64.72% 8.39% 56.32% 7.23E-06 - <td>NZ_AJZS01000015.1</td> <td>952</td> <td>+</td> <td>13.70%</td> <td>22.02%</td> <td>8.33%</td> <td>6.03E-06</td> <td>HMPREF1322_RS00885</td> <td>ı</td> <td>U32 family peptidase</td> <td>_oN</td> <td>HMPREF1322_RS00880,HMPREF1322_RS00885</td>	NZ_AJZS01000015.1	952	+	13.70%	22.02%	8.33%	6.03E-06	HMPREF1322_RS00885	ı	U32 family peptidase	_o N	HMPREF1322_RS00880,HMPREF1322_RS00885
14698 + 26.82% 44.78% 17.96% 7.90E-06 IMPREF1322_RS00730 - Hypothetical protein Yes IMPREF1322_RS00731 1044 - 10.78% 5.52% 8.29E-06 IMPREF1322_RS00730 - IMPORTEGIAL Yes IMPREF1322_RS00731 14542 + 15.67% 34.20% 18.53% 8.76E-06 IMPREF1322_RS00730 - Hypothetical protein Yes IMPREF1322_RS00732 4471 - 17.52% 22.93% 5.41% 9.62E-06 - - - - - IMPREF1322_RS08364 1625 - 26.00% 9.52% 16.48% 9.79E-06 IMPREF1322_RS04325 - - - - IMPREF1322_RS083864	NZ_AJZS01000050.1	1920	ı	64.72%	8.39%	56.32%	7.23E-06		ı	1	ı	HMPREF1322_RS04325,HMPREF1322_RS04330
1044 10.78% 5.52% 8.29E-06 HMPREF1322_RS04090 - MBOAT family protein Yes HMPREF1322_RS04090 - Hypothetical protein Yes HMPREF1322_RS04090 HMPREF1322_RS04090 HMPREF1322_RS04090 - Hypothetical protein Yes HMPREF1322_RS04090 HMPREF1322_RS04090 - HMPREF1322_RS04090 HMPREF1322_RS04090 HMPREF1322_RS04090 HMPREF1322_RS04090 HMPREF1322_RS04090 HMPREF1322_RS04090 Yes HMPREF1322_RS04090 HMPREF1322_RS04090 HMPREF1322_RS04090 Yes Yes HMPREF1322_RS04090 Yes Yes HMPREF1322_RS04090 Yes	NZ_AJZS01000011.1	14698	+	26.82%	44.78%	17.96%	7.90E-06	HMPREF1322_RS00730	ı	Hypothetical protein	Yes	HMPREF1322_RS00725,HMPREF1322_RS00730,
1044 - 10.78% 5.27% 5.52% 8.29E-06 HMPREF1322_RS04090 - MBOAT family protein Yes HMPREF1322_RS04090 14542 + 15.67% 34.20% 18.53% 8.76E-06 HMPREF1322_RS00730 - Hypothetical protein Yes HMPREF1322_RS00731 HMPREF1322_RS00732 - Hypothetical protein Yes HMPREF1322_RS00733 - 17.52% 22.93% 5.41% 9.62E-06 - HMPREF1322_RS04325 - DUF2436 domain-containing protein Yes HMPREF1322_RS03866												HMPREF1322_RS00735
14542 + 15.67% 34.20% 18.53% 8.76E-06 HMPREF1322_RS00730 - Hypothetical protein Yes HMPREF1322_RS00732 HMPREF1322_RS00733 - HMPREF1322_RS00733 HMPREF1322_RS00733 - HMPREF1322_RS03866 - HMPREF1322_RS03873 - DUF2436 domain-containing protein Yes HMPREF1322_RS034325 - DUFA436 domain-containing Protein	NZ_AJZS01000046.1	1044	ı	10.78%	5.27%	5.52%	8.29E-06	HMPREF1322_RS04090	ı	MBOAT family protein	Yes	HMPREF1322_RS04090,HMPREF1322_RS04095
HMPREF1322_RS00735 4471 - 17.52% 22.93% 5.41% 9.62E-06 HMPREF1322_RS03860 HMPREF1322_RS03875 1625 - 26.00% 9.52% 16.48% 9.79E-06 HMPREF1322_RS04325 - DUF2436 domain-containing protein Yes HMPREF1322_RS0432	NZ_AJZS01000011.1	14542	+	15.67%	34.20%	18.53%	8.76E-06	HMPREF1322_RS00730	ı	Hypothetical protein	Yes	HMPREF1322_RS00725,HMPREF1322_RS00730,
4471 - 17.52% 22.93% 5.41% 9.62E-06 - - - - - - HMPREFI 322_RS03867 HMPREFI 322_RS03875 - 26.00% 9.52% 16.48% 9.79E-06 HMPREFI 322_RS04325 - DUF2436 domain-containing protein Yes HMPREFI 322_RS04321												HMPREF1322_RS00735
HMPREF1322_RS0387: 1625 – 26.00% 9.52% 16.48% 9.79E-06 HMPREF1322_RS04325 – DUF2436 domain-containing protein Yes HMPREF1322_RS0432:	NZ_AJZS01000041.1	4471	ı	17.52%	22.93%	5.41%	9.62E-06	1	ı	1	ı	HMPREF1322_RS03860,HMPREF1322_RS03870,
1625 – 26.00% 9,52% 16.48% 9,79E-06 HMPREF1322_RS04325 – DUF2436 domain-containing protein Yes HMPREF1322_RS0432 ¹												HMPREF1322_RS03875
	NZ_AJZS01000050.1	1625	ı	26.00%	9.52%	16.48%	9.79E-06	HMPREF1322_RS04325	ı	DUF2436 domain-containing protein	Yes	HMPREF1322_RS04325,HMPREF1322_RS04330

Downloaded from https://journals.asm.org/journal/msystems on 26 January 2024 by 2.126.43.57.

mSystems

TABLE 4 Differentially methylated cytosines (5mC) identified in *P. gingivalis* W50, selecting for a minimum mean 5% methylation difference between experimental conditions (false discovery rate = 5% and minimum 10× coverage) (*Continued*)

Contig	Position Strand	Strand	Mean %	Mean %	% methylation	P-value	Gene ID (locus tag)	Gene symb	Gene symbol Gene product	Gene on the	Gene on the Genes \pm 1 kb away, both strands
			methylation:	methylation: methylation:	difference					same strand	Þ
			Ħ	EXH							
NZ_AJZS01000015.1	78713		64.82%	58.15%	6.67%	1.08E-05	HMPREF1322_RS01240	1	Iron ABC transporter permease	Yes	HMPREF1322_RS01240,HMPREF1322_RS01245
NZ_AJZS01000011.1	13730	+	13.59%	58.15%	44.56%	1.13E-05	HMPREF1322_RS00725	ı	Lactate utilization protein	Yes	HMPREF1322_RS00720,HMPREF1322_RS00725,
											HMPREF1322_RS00730
NZ_AJZS01000050.1	2262	ı	53.40%	9.81%	43.59%	1.20E-05	HMPREF1322_RS04330	ı	Nucleoside permease	Yes	HMPREF1322_RS04325,HMPREF1322_RS04330
NZ_AJZS01000011.1	14669	+	7.23%	19.84%	12.61%	1.28E-05	HMPREF1322_RS00730	ı	Hypothetical protein	Yes	HMPREF1322_RS00725,HMPREF1322_RS00730,
											HMPREF1322_RS00735
NZ_AJZS01000089.1	26	+	0.00%	9.03%	9.03%	1.34E-05	HMPREF1322_RS08455	ı	IS5/IS1182 family transposase	Yes	HMPREF1322_RS08455,HMPREF1322_RS08460
NZ_AJZS01000011.1	14706	+	2.91%	21.70%	18.79%	1.52E-05	HMPREF1322_RS00730	ı	Hypothetical protein	Yes	HMPREF1322_RS00725,HMPREF1322_RS00730,
											HMPREF1322_RS00735
NZ_AJZS01000050.1	2002	ı	58.99%	4.81%	54.18%	1.57E-05		ı	I	ı	HMPREF1322_RS04325,HMPREF1322_RS04330
NZ_AJZS01000036.1	5418	+	22.76%	14.46%	8.30%	1.59E-05	HMPREF1322_RS03420	ı	YjgP/VjgQ family permease	No	HMPREF1322_RS03410,HMPREF1322_RS03415,
											HMPREF1322_RS03420,HMPREF1322_RS03425
NZ_AJZS01000050.1	2101	ı	53.34%	4.65%	48.69%	1.74E-05	HMPREF1322_RS04330	ı	Nucleoside permease	Yes	HMPREF1322_RS04325,HMPREF1322_RS04330
NZ_AJZS01000080.1	123	+	12.46%	0.00%	12.46%	1.76E-05	HMPREF1322_RS07835	ı	Hypothetical protein	Yes	HMPREF1322_RS07835,HMPREF1322_RS07840,
											HMPREF1322_RS07845
NZ_AJZS01000080.1	124	+	12.46%	0.00%	12.46%	1.76E-05	HMPREF1322_RS07835	ı	Hypothetical protein	Yes	HMPREF1322_RS07835,HMPREF1322_RS07840,
											HMPREF1322_RS07845
NZ_AJZS01000011.1	14693	+	14.07%	38.73%	24.67%	1.77E-05	HMPREF1322_RS00730	ı	Hypothetical protein	Yes	HMPREF1322_RS00725,HMPREF1322_RS00730,
											HMPREF1322_RS00735
NZ_AJZS01000069.1	3434	1	51.80%	41.48%	10.32%	1.97E-05	HMPREF1322_RS06465	ı	Hypothetical protein	Yes	HMPREF1322_RS06460,HMPREF1322_RS06465,
											HMPREF1322_RS06470
NZ_AJZS01000013.1	2448	1	11.90%	17.41%	5.51%	2.20E-05	HMPREF1322_RS00790	gyrA	DNA gyrase subunit A	Yes	HMPREF1322_RS00785,HMPREF1322_RS00790
NZ_AJZS01000050.1	1769	ı	49.12%	2.56%	46.56%	2.20E-05	ı	ı	1	ı	HMPREF1322_RS04325,HMPREF1322_RS04330
NZ_AJZS01000066.1	22943	+	70.43%	31.90%	38.53%	2.21E-05	HMPREF1322_RS06180	ı	Ppx/GppA family phosphatase	No	HMPREF1322_RS06175,HMPREF1322_RS06180,
											HMPREF1322_RS06185
NZ_AJZS01000050.1	797	ı	38.96%	13.79%	25.16%	2.31E-05	HMPREF1322_RS04325	ı	DUF2436 domain-containing protein	Yes	HMPREF1322_RS04325
NZ_AJZS01000011.1	18653	+	4.65%	18.69%	14.04%	2.34E-05	HMPREF1322_RS00745	ı	ABC transporter ATP-binding protein	No	HMPREF1322_RS00740,HMPREF1322_RS00745
NZ_AJZS01000009.1	3668	+	12.68%	21.61%	8.93%	2.40E-05	HMPREF1322_RS00555	ı	DEAD/DEAH box helicase family protein	_o N	HMPREF1322_RS00555,HMPREF1322_RS00560
NZ_AJZS01000011.1	13430	+	9.65%	38.76%	29.11%	2.55E-05	HMPREF1322_RS00725	ı	Lactate utilization protein	Yes	HMPREF1322_RS00720,HMPREF1322_RS00725
NZ_AJZS01000050.1	2103	ı	61.60%	6.56%	55.04%	2.66E-05	HMPREF1322_RS04330	1	Nucleoside permease	Yes	HMPREF1322_RS04325,HMPREF1322_RS04330
^a LiH, growth in limited hemin; ExH, growth in excess hemin.	ed hemin; E	XH, grov	vth in excess h	nemin.							

cases. The 15 DEGs with DMAs under-expressed in excess hemin included the hypothetical protein HMPREF1322_RS00730 (W83: PG1173) in the lactate utilization cluster, the lactate utilization protein HMPREF1322_RS00725 (W83: PG1172), the 4-alpha-glucanotransferase HMPREF1322_RS03650 (W83: PG0767), and ABC transporter protein gene cluster HMPREF1322 RS00745 (W83: PG1176) and HMPREF1322 RS00740 (W83: PG1175) (Table 6). Seven of the 15 genes had DMAs located upstream of the gene, and six of these showed increased 6mA accompanied by decreased gene expression, indicating a potential regulatory effect of 6mA in dampening the expression of P. gingivalis genes according to hemin availability in the bacterium's microenvironment. Most DMAs annotated to under-expressed genes had higher adenine methylation in excess hemin (84%) regardless of their location with respect to gene structure. In comparison to all-context DMAs, the "GATC"-DMMs were annotated to 14 DEGs (six and eight DEGs respectively over and under-expressed; Tables S8 and S9). DEGs associated "GATC"-DMMs included among others the 4-alpha-glucanotransferase HMPREF1322_RS03650 (W83: PG0767) mentioned immediately above. However, only four genes had "GATC"-DMMs upstream their start site, and another two genes showed greater methylation associated with lower expression overall. This suggests very limited potential for a role of GATC methylation in the regulation of gene expression in P. gingivalis W50 in response to hemin availability.

One over-expressed and 11 under-expressed genes also had DMCs within 1 kb of the gene (Table 7 and 8). Two of the 11 under-expressed genes had DMCs upstream of the gene (Table 8) with increased methylation levels observed for all 11 genes. Moreover, 95% of DMCs annotated to under-expressed genes had increased cytosine methylation in excess hemin regardless of their location in relation to the gene. This is consistent with results from 6mA, although knowledge of gene regulation by 5mC methylation in bacteria remains limited.

Six DEGs had both DMAs and DMCs in their gene body or within ± 1 kb of the gene (Fig. 7), and a subset of these DEGs clustered in a genomic region that includes the lactate utilization gene cluster (Fig. 6). The six DEGs include the Ppx/GppA family phosphatase HMPREF1322_RS06180 (W83: PG1739), over-expressed in excess hemin, and the hypothetical protein HMPREF1322_RS00730 (W83: PG1173), lactate utilization protein HMPREF1322_RS00725 (W83: PG1172), 4-alpha-glucanotransferase HMPREF1322_RS03650 (W83: PG0767), ABC transporter protein HMPREF1322_RS00745 (W83: PG1176), and HMPREF1322_RS00740 (W83: PG1175), which were under-expressed in excess hemin (Table 9). We assessed whether genome-wide DEGs were enriched for DMAs and DMCs, but did not observe a significant enrichment overall (OR = 0.77 (95% CI: 0.45, 1.31), P-value = 0.38 and OR = 1.13 (95% CI: 0.49, 2.47), P-value = 0.85, respectively). However, we observed strong evidence for overall differences in upstream or gene body DNA methylation levels at specific DEGs overlapping DMAs and DMCs (Supplemental Note, Figures G and H).

For all DEGs that also harbored DMAs or DMCs, we analyzed the overall levels of adenine (Supplemental Note, Figure G) and cytosine (Supplemental Note, Figure H) methylation upstream (–100 bp), downstream (+100 bp), and in the gene body. Differential adenine and cytosine methylation were observed across all regions analyzed for the lactate utilization protein HMPREF1322_RS00725 (W83: PG1172) (upstream; gene body; downstream; Table 9; Fig. 6). Differential adenine and cytosine methylation were also observed in the gene body of the ABC transporters HMPREF1322_RS00740 (W83: PG1175) and HMPREF1322_RS00745 (W83: PG1176) and hypothetical protein HMPREF1322_RS00730 (W83: PG1173) (Supplemental Note, Figures G and H). These ABC transporter proteins are located directly downstream of a lactate utilization gene cluster, which includes the lactate utilization protein and hypothetical protein, possibly highlighting a key region of the *P. gingivalis* genome regulated by DNA methylation (Fig. 6). Overall changes in adenine and/or cytosine methylation were also, for example, observed in the body of the 4–alpha–glucanotransferase HMPREF1322_RS03650 (W83:

PG0767) gene, and upstream the ABC transporter HMPREF1322_RS00740 (W83: PG1175) (Supplemental Note, Figures G and H).

DISCUSSION

We identified a significant impact of hemin availability in the growth medium on the *P. gingivalis* epigenome and transcriptome. Growth of *P. gingivalis* is restricted in the healthy gingival crevice due to a tight restriction by the host on hemin availability. However, during increasing inflammation in periodontal disease, the availability of heme-containing molecules is substantially increased. Hemin-dependent differentially modified signatures were identified for gene expression, as well as for 6mA and 5mC methylation profiles. Comparison of the signals highlighted a cluster of coordinated changes in genes related to lactate utilization and in ABC transporters. The findings identify putative bacterial DNA methylation signatures that may play a regulatory role in the expression of genes, in response to hemin availability.

Many of the genes that were over-expressed in excess hemin encoded proteins that contain iron as part of their tertiary structures or have iron/hemin binding domains. These include Lys-gingipain (Kgp; Table S1) that is known to be involved in iron acquisition and virulence (14). Kgp is a large multi-domain protein, which is able to hydrolyze hemoglobin, bind hemin via its hemagglutinin domains, and facilitate its acquisition and conversion into the black pigment (μ-oxo bishaem) at the cell surface (40). Previous work confirmed virulence changes in response to hemin availability under similar experimental conditions (21).

Over-expressed members of the ABC transport complex (Fig. 6B and Table 6), forming a classical operon, may potentially represent a novel hemin or alternative solute acquisition system that may influence the cellular phenotype. The enhanced expression of thiamine phosphate synthase is not only limited to this gene (Table S1) of the pathway; the contig also encodes ThiH, ThiG, ThiC, ThiS, and a hypothetical protein, all arranged in an apparent operon. Thus, the biosynthesis of the energy co-factor thiamine, vitamin B1, may constitute an important aspect of *P. gingivalis* metabolism. Rubrerythrin offers protection of the anaerobe, *P. gingivalis*, against the toxicity of molecular oxygen and hydrogen peroxide; an isogenic mutant is labile under these conditions (41). In addition, there appears to be a preference for succinate/fumarate and a-ketoglutarate utilization (Table S1).

Many genes under-expressed in excess hemin were involved in hemin binding or transport. Some genes also encoded for DNA transfer functions such as TraC, TraE, TraF, and TraJ. Interestingly, the gene encoding the largest protein component of the T9SS, Sov (SprA), and (42) also genes encoding OmpH, PorN (GldN), and PorX along with five cargo proteins, were under-expressed in excess hemin (Table S2). Sov and PorN are both major structural proteins of the T9SS located at the outer membrane. PorX is a member of a two-component regulator system (PorX/PorY) that governs transcription of numerous genes including those encoding the T9SS (42). OmpH is a cargo protein of the T9SS able to cause activation of proinflammatory cytokines (interleukin-6 and tumor necrosis factor α) in macrophages (43). The T9SS complex transports over 30 cargo proteins, including known virulence factors, with a CTD signal motif, to the external environment (44). However, the entire structure and organization of this system is not fully elucidated, and it is not currently clear why only a subset of this multi-protein complex and a limited number of the numerous cargo proteins are under-expressed in excess hemin. T9SS has many components with differences in relative stoichiometry. Furthermore, different genomic regions and operons contribute to express components of the T9SS (45), introducing a further level of complexity such as variable response of individual promoters to different environmental exposures.

The gene encoding the long fimbriae surface appendage, FimA, together with its accessory proteins of the *fim* operon were also under-expressed in excess hemin. The genes encoding regulatory proteins [e.g., AraC, TetR (AcrR), and LuxR] followed a similar expression pattern. Many transposases were also under-expressed in excess hemin,




FIG 7 Overlap of genes with differentially expressed genes (DEGs), differentially methylated adenine sites (DMAs), and differentially methylated cytosines (DMCs) in excess hemin conditions.

whereas no transposases were over-expressed in excess hemin, suggesting that the expression of these mobile elements is a characteristic of a stress environment where access to iron is limited. Time of incubation in the chemostat can lead to amplified expression changes in some of the genes (e.g., the ABC transporter genes in the lactate utilization cluster; Supplemental Note, Figure I).

We compared our results with two previous studies exploring expression (11) and proteomic (12) differences in P. gingivalis according to hemin availability in the media (Supplemental Note, Figure J). We observed that both Anaya-Bergman et al. (11) and Veith et al. (12) previously reported changes in the expression of the phosphomethylpyrimidine synthase ThiC, involved in thiamine biosynthesis, under excess hemin conditions. Moreover, both studies also reported underexpressed levels of the genes coding peroxiredoxin and a phosphotransferase. Separately, Anaya-Bergman et al. (11) shared three over-expressed genes with our study, i.e., the 2-iminoacetate synthase thiH, thiazole synthase thiG and a thiamine phosphate synthase (W83: PG2109/HMPREF1322_RS02110), and Veith et al. (12) results matched three of the over-expressed genes identified by us, i.e., the rubrerythrin family protein HMPREF1322_RS04040 (W83: PG0195) and two hypothetical proteins (W83: PG0717/HMPREF1322 RS01045 and PG2105/HMPREF1322 RS02130). Veith et al. (12) proteomic results also identified proteins for 11 additional underexpressed genes found in our study. These genes coded the cobaltochelatase subunit CobN (W83: PG1553/HMPREF1322_RS06780), the heme-binding protein HmuY (W83: PG1551/HMPREF1322 RS06790), a histidinol phosphate phosphatase (W83: PG0555/HMPREF1322_RS03860), an MMPL family transporter (W83: PG1180/ HMPREF1322_RS06005), a peroxiredoxin (W83: PG0618/HMPREF1322_RS06360), a phosphoribosyltransferase (W83: PG1513/HMPREF1322_RS06960), a phosphotransferase (W83: PG0456/HMPREF1322_RS00135), a T9SS type A sorting domain-containing protein (W83: PG0495/HMPREF1322_RS03170), a TonB-dependent receptor (W83: PG1552/ HMPREF1322_RS06785), a transporter protein (W83: PG1626/HMPREF1322_RS06460), and three hypothetical proteins (W83: PG0350/HMPREF1322_RS02675, W83: PG0613/HMPREF1322_RS06380, and W83: PG1555/HMPREF1322_RS06770). The HMPREF1322_RS06770 hypothetical protein, the HMPREF1322_RS06360 peroxiredoxin, and the HMPREF1322_RS06460 transporter respectively matched the PG1555 MotA/ TolQ/ExbB proton channel family, PG0618 alkyl peroxide reductase AhpC, and PG1626 FADL outer membrane receptor protein annotated in P. gingivalis W83 strain genome.

Epigenetic mechanisms, including the methylation of specific DNA sequences by DNA methyltransferases, allow unicellular organisms to respond rapidly to environmental stresses (46). Here, we showed that both adenines and cytosines can be differentially methylated in *P. ginqivalis* according to hemin availability in its microenvironment. Unlike

TABLE 5 Genes over-expressed in excess hemin conditions with differentially methylated adenine sites (>1.5 log2 fold change, >5% methylation difference, false discovery rate = 5%)"

Locus tag	Gene	Gene Gene product	Contig	Gene	Gene S	Strand	Strand Methylated	Strand	Distance	10	DE analysis	S		DM analysis	rsis	
	symbol	_		start	end	Expr.	position	meth.	meth.	baseMean	LFC	P-value	Mean %	Mean %	%	P-value
													methylation:	methylation: methylation: methylation	methylation	
													ΗI	ExH	difference	
HMPREF1322_RS07305		SDR family oxidoreductase NZ_AJZS0100007	NZ_AJZS01000071.1	5169	2900		5863	,	694	39,671.02	3.52	3.70E-20	62.88%	80.42%	17.54%	6.37E-06
HMPREF1322_RS07315	pdxA	4-Hydroxythreonine-4-phos- NZ_AJZS01000071	NZ_AJZS01000071.1	6386	7483	ı	5863	ı	-523	10,873.97	2.21	2.04E-19	62.88%	80.42%	17.54%	6.37E-06
		phate dehydrogenase PdxA	_													
HMPREF1322_RS06180	I	Ppx/GppA family	NZ_AJZS01000066.1	22201	23108	ı	22242	ı	41	914.83	1.59	2.19E-12	15.95%	%08.96	80.86%	3.66E-07
		phosphatase														
HMPREF1322_RS06180	I	Ppx/GppA family	NZ_AJZS01000066.1	22201	23108	ı	22938	ı	737	914.83	1.59	2.19E-12	85.99%	37.41%	48.59%	4.56E-06
		phosphatase														
HMPREF1322_RS01480	I	tRNA-Thr	NZ_AJZS01000017.1	23424	23496	ı	23369	ı	-55	362.80	2.29	2.35E-12	13.67%	18.77%	5.10%	1.66E-05
HMPREF1322_RS01485	I	Hypothetical protein	NZ_AJZS01000017.1	23557	24009	ı	23369	ı	-188	2,236.75	2.55	9.57E-12	13.67%	18.77%	5.10%	1.66E-05
HMPREF1322_RS04280	dnaE	DNA polymerase III subunit NZ_AJZS01000048.1	NZ_AJZS01000048.1	883	4569	ı	4837	ı	3954	4,976.97	1.52	1.59E-09	0.00%	9.02%	9.02%	1.15E-05
		alpha														
HMPREF1322_RS04100	I	Hypothetical protein	NZ_AJZS01000046.1	2632	4023	ı	4018	ı	1386	3,442.27	1.59	9.47E-09	3.69%	15.60%	11.90%	6.52E-06
HMPREF1322_RS04100	I	Hypothetical protein	NZ_AJZS01000046.1	2632	4023	ı	4605	ı	1973	3,442.27	1.59	9.47E-09	%69'9	%00:0	%69'9	1.30E-05
HMPREF1322_RS09370	mf	5S ribosomal RNA	NZ_AJZS01000099.1	3390	3500	ı	2869	1	-521	5,793.67	1.71	6.69E-04	25.68%	47.10%	8.58%	1.41E-06

^aDE analysis, results from the differential expression analysis; Distance Meth, distance of the methylated position to the gene start site in base pairs, negative values indicate upstream location; DM analysis, results from the differential methylation analysis; ExH, growth in excess hemin; LFC, log 2 fold change; LiH, growth in limited hemin; Strand of the gene; Strand Meth, strand of the methylated position.

mSystems

TABLE 6 Genes under-expressed in excess hemin conditions with differentially methylated adenine sites (<-1.5 LFC, >5% methylation difference, false discovery rate = 5%)?

Locus tag	Gene	Gene product	Contig	Gene start	Gene start Gene end Strand		Methylated	Strand Distance	stance	□	DE analysis			DM analysis	10	
	symbol					Expr.	position	meth. n	meth. ba	baseMean	FC	P-value	Mean %	Mean %	% Methylation	P-value
													methylation: LiH	methylation: ExH	difference	
HMPREF1322_RS00745	1	ABC transporter ATP-binding NZ_AJZS01000011.1	NZ_AJZS01000011.1	17886	19607	1	17614	+	-272 3	3,619.54	-4.27	2.40E-57	2.76%	16.42%	13.66%	1.15E-05
		protein														
HMPREF1322_RS00745	ı	ABC transporter ATP-binding NZ_AJZS01000011.1	NZ_AJZS01000011.1	17886	19607	ı	19392	+	1506 3	3,619.54	-4.27	2.40E-57	7.54%	25.19%	17.66%	1.14E-05
		protein														
HMPREF1322_RS00730	ı	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	13584	+	-894	1,091.42	-3.38	5.01E-41	2.40%	14.66%	12.25%	5.18E-07
HMPREF1322_RS00730	ı	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	13965	+	-513 1	1,091.42	-3.38	5.01E-41	3.83%	37.85%	34.02%	4.16E-06
HMPREF1322_RS00730	ı	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	14019	+	-459 1	1,091.42	-3.38	5.01E-41	1.48%	34.21%	32.73%	1.48E-05
HMPREF1322_RS00730	ı	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	14200	+	-278 1	1,091.42	-3.38	5.01E-41	5.92%	18.54%	12.62%	8.66E-06
HMPREF1322_RS00730	ı	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	14323	+	-155 1	1,091.42	-3.38	5.01E-41	2.43%	19.81%	17.38%	1.65E-05
HMPREF1322_RS00730	ı	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	14324	+	-154 1	1,091.42	-3.38	5.01E-41	1.76%	17.10%	15.34%	3.75E-06
HMPREF1322_RS00730	ı	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	14487	+	9	1,091.42	-3.38	5.01E-41	0.97%	19.32%	18.35%	2.62E-06
HMPREF1322_RS00730	ı	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	14511	+	33 1	1,091.42	-3.38	5.01E-41	4.96%	46.35%	41.39%	3.60E-06
HMPREF1322_RS00730	ı	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	14512	+	34 1	1,091.42	-3.38	5.01E-41	5.03%	41.65%	36.62%	1.56E-05
HMPREF1322_RS00730	ı	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	14644	+	166 1	1,091.42	-3.38	5.01E-41	5.20%	29.07%	23.87%	4.28E-06
HMPREF1322_RS00730	ı	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	14744	+	266 1	1,091.42	-3.38	5.01E-41	2.00%	28.52%	26.52%	1.52E-06
HMPREF1322_RS00730	ı	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	15471	+	993 1	1,091.42	-3.38	5.01E-41	7.97%	28.75%	20.78%	1.11E-05
HMPREF1322_RS00725	ı	Lactate utilization protein	NZ_AJZS01000011.1	13105	14472	+	13236	+	131	911.64	-2.93	5.26E-38	6.84%	52.42%	45.58%	5.83E-06
HMPREF1322_RS00725	ı	Lactate utilization protein	NZ_AJZS01000011.1	13105	14472	+	13584	+	479	911.64	-2.93	5.26E-38	2.40%	14.66%	12.25%	5.18E-07
HMPREF1322_RS00725	ı	Lactate utilization protein	NZ_AJZS01000011.1	13105	14472	+	13965	+	860	911.64	-2.93	5.26E-38	3.83%	37.85%	34.02%	4.16E-06
HMPREF1322_RS00725	ı	Lactate utilization protein	NZ_AJZS01000011.1	13105	14472	+	14019	+	914	911.64	-2.93	5.26E-38	1.48%	34.21%	32.73%	1.48E-05
HMPREF1322_RS00725	ı	Lactate utilization protein	NZ_AJZS01000011.1	13105	14472	+	14200	+	1095	911.64	-2.93	5.26E-38	5.92%	18.54%	12.62%	8.66E-06
HMPREF1322_RS00725	ı	Lactate utilization protein	NZ_AJZS01000011.1	13105	14472	+	14323	+	1218	911.64	-2.93	5.26E-38	2.43%	19.81%	17.38%	1.65E-05
HMPREF1322_RS00725	ı	Lactate utilization protein	NZ_AJZS01000011.1	13105	14472	+	14324	+	1219	911.64	-2.93	5.26E-38	1.76%	17.10%	15.34%	3.75E-06
HMPREF1322_RS00725	ı	Lactate utilization protein	NZ_AJZS01000011.1	13105	14472	+	14487	+	1382	911.64	-2.93	5.26E-38	%26:0	19.32%	18.35%	2.62E-06
HMPREF1322_RS00725	ı	Lactate utilization protein	NZ_AJZS01000011.1	13105	14472	+	14511	+	1406	911.64	-2.93	5.26E-38	4.96%	46.35%	41.39%	3.60E-06
HMPREF1322_RS00725	ı	Lactate utilization protein	NZ_AJZS01000011.1	13105	14472	+	14512	+	1407	911.64	-2.93	5.26E-38	5.03%	41.65%	36.62%	1.56E-05
HMPREF1322_RS00725	ı	Lactate utilization protein	NZ_AJZS01000011.1	13105	14472	+	14644	+	1539	911.64	-2.93	5.26E-38	5.20%	29.07%	23.87%	4.28E-06
HMPREF1322_RS00725	ı	Lactate utilization protein	NZ_AJZS01000011.1	13105	14472	+	14744	+	1639	911.64	-2.93	5.26E-38	2.00%	28.52%	26.52%	1.52E-06
HMPREF1322_RS00725	ı	Lactate utilization protein	NZ_AJZS01000011.1	13105	14472	+	15471	+	2366	911.64	-2.93	5.26E-38	7.97%	28.75%	20.78%	1.11E-05
HMPREF1322_RS01975	ı	O-acetyl-ADP-ribose	NZ_AJZS01000021.1	7184	7678	ı	7225	+	41 6	6,623.03	-2.30	2.87E-18	11.70%	17.64%	5.94%	1.67E-05
		deacetylase														
HMPREF1322_RS02315	ı	Tetratricopeptide repeat	NZ_AJZS01000025.1	5372	7181	ı	6136	+	764 11	11,707.30	-3.03	4.40E-17	20.06%	0.00%	20.06%	1.32E-05
		protein														
HMPREF1322_RS03650	ı	4-Alpha-glucanotransferase NZ_AJZS01000038.1	NZ_AJZS01000038.1	2961	4847	1	3559	ı	5 865	5,951.70	-2.22	5.69E-14	4.43%	89.64%	85.21%	7.67E-08
HMPREF1322_RS03650	ı	4-Alpha-glucanotransferase	NZ_AJZS01000038.1	2961	4847	ı	3560	I	5 665	5,951.70	-2.22	5.69E-14	1.45%	86.22%	84.77%	5.31E-06
														0)	(Continued on next page)	next page)

Downloaded from https://journals.asm.org/journal/msystems on 26 January 2024 by 2.126.43.57.

TABLE 6 Genes under-expressed in excess hemin conditions with differentially methylated adenine sites (LFC, >5% methylation difference, false discovery rate = 5%) (Continued)

Locus tag	Gene	Gene Gene product	Contig	Gene start	Sene end	Strand	Gene start Gene end Strand Methylated Strand Distance	Strand D	istance	٥	DE analysis			DM analysis		
	symbol					Expr.	position	meth. meth.		baseMean	LFC	P-value	Mean %	Mean %	% Methylation P-value	P-value
													methylation: LiH	methylation: ExH	difference	
HMPREF1322_RS02310		Response regulator	NZ_AJZS01000025.1	4676	5359	1	6136	+	1460 1	10,536.03	-1.99	1.34E-13	20.06%	0.00%	20.06%	1.32E-05
		transcription factor														
HMPREF1322_RS01980	ı	UDP-2,3-diacylglucosamine NZ_AJZS01000021.1	NZ_AJZS01000021.1	7760	8548	ı	7225	+	-535	13,336.64	-1.78	2.46E-13	11.70%	17.64%	5.94%	1.67E-05
		diphosphatase														
HMPREF1322_RS07250	ı	Site-specific integrase	NZ_AJZS01000069.1	173000	174202	+	173248	ı	248	320.75	-1.58	8.34E-11	37.82%	19.39%	18.43%	1.14E-05
HMPREF1322_RS00740	ı	ABC transporter ATP-binding NZ_AJZS01000011.1	NZ_AJZS01000011.1	16133	17839	ı	15471	+	-662	7,059.72	-2.68	5.06E-10	7.97%	28.75%	20.78%	1.11E-05
		protein														
HMPREF1322_RS00740	I	ABC transporter ATP-binding NZ_AJZS01000011.1	NZ_AJZS01000011.1	16133	17839	ı	17614	+	1481	7,059.72	-2.68	5.06E-10	2.76%	16.42%	13.66%	1.15E-05
		protein														
HMPREF1322_RS09495	I	Hypothetical protein	NZ_AJZS01000101.1	10189	10749	+	9445	ı	-744	6,645.00	-2.53	3.50E-09	%00.05	75.93%	25.93%	9.71E-06
HMPREF1322_RS07780	ı	MBL fold metallo-hydrolase	NZ_AJZS01000079.1	4600	5244	+	3864	ı	-736	2,319.58,	-2.32	2.51E-06	76.11%	60.84%	15.27%	1.52E-05
HMPREF1322_RS08150	I	Blal/Mecl/CopY family	NZ_AJZS01000085.1	6031	6411	+	7204	ı	1173	403.18	-1.74	2.90E-06	33.33%	59.05%	25.72%	1.12E-05
		transcriptional regulator														
HMPREF1322_RS10055	ı	Hypothetical protein	NZ_AJZS01000050.1	56011	56172	+	55602	+	-409	18.27	-1.91	7.10E-04	53.36%	63.37%	10.01%	1.98E-07
HMPREF1322_RS09820	ı	Hypothetical protein	NZ_AJZS01000020.1	830	1045	+	1186	+	356	251.64	-1.72	1.04E-03	6.83%	0.00%	6.83%	1.66E-06
9 - 1	14		4		44 44.	-				the beauty		-				

^aDE analysis, results from the differential expression analysis; Distance Meth, distance of the methylated position to the gene start site in base pairs, negative values indicate upstream location; DM analysis, results from the differential methylation analysis; ExH, growth in excess hemin; LFC, log 2 fold change; LiH, growth in limited hemin; Strand of the gene; Strand Meth, strand of the methylated position.

in eukaryotes, in bacteria, 5mC is not the dominant DNA modification and instead exists alongside 4mC and 6mA, the latter being the most prevalent modification in prokaryotes (47). Here, we characterized both 6mA and 5mC, and verified higher levels of adenine methylation (mean = 23% and median = 13% for 6mA genome-wide) in comparison to cytosine methylation (mean = 18% and median = 13% for 5mC genome-wide). However, lack of previous DNA methylation studies in P. gingivalis and a general lack of knowledge of the most common genetic motifs targeted by DNA methyltransferases (DNMTs) in this bacterium limited the analyses that we could undertake, and may impact some of the interpretation of data. We analyzed DNA methylation changes in Dam/Dcm motifs (mean = 8% and median = 13% for Dam; mean = 0.02% and median = 0% for Dcm genomewide) to investigate possible Dam- and Dcm-like DNA methylation in P. gingivalis. However, we observed only limited evidence for Dam-like "GATC" methylation effects that overlapped differential gene expression. Alternatively, and because no standard model for methylation calling in P. gingivalis exists, we used Nanopore reads and allcontext predictive models in Tombo to estimate the proportion of reads harboring methylated bases in our study. All-context models in turn introduced a higher degree of uncertainty in methylation calling in our analysis. Additionally, we used proportion of methylated reads as an estimate of methylation levels in each sample of bacterial cells. In our data, most positions at which DNA methylation was detected were not fully methylated or demethylated, pointing to presence of heterogeneity in the level of DNA methylation across different bacterial cells from the same culture sample (Supplemental Note, Figures K and L). Heterogenous DNA methylation in subpopulations from a single colony can be responsible for the phenotypic variation observed during a bacterium's adaptation to a new environment (46). In this case, the DNA methylation levels observed could indicate a flexible response to hemin that is implicated in the colonization of the gingival crevice by P. gingivalis in vivo. However, further work is needed to test the role of methylation heterogeneity in *P. gingivalis*.

DNA methylation has historically been associated with bacterial DNA restriction-modification systems, which protect bacterial cells from foreign DNAs (46). More recently, DNA methylation has also been shown to play important roles in other aspects of bacterial biology such as timing of DNA replication, timing of transposition, and conjugal transfer of plasmids, DNA repair, and cell partitioning, and regulation of gene expression (46). Less is known, however, about how widespread the role of DNA methylation is in virulence and pathogenesis. Prior evidence suggests that the activity of DNMTs such as Dam can, for example, affect virulence in a number of pathogens including *E. coli, Salmonella* spp., *Yersinia pseudotuberculosis*, and *Vibrio cholerae* (48).

Here, we showed that the availability of hemin—a critical micronutrient that modulates the expression of virulence factors in P. gingivalis—is linked to changes in the DNA methylome of this bacterium. We also showed that methylation changes were coordinated to alterations in the expression of lactate utilization and ABC transporter genes; however, their exact role in P. gingivalis remains unknown. Porphyromonas gingivalis is assaccharolytic and utilizes amino acids/peptides as the major source of nutrition (49). Hence, any changes in lactate utilization are unconnected to the fermentation of monosaccharides via glycolysis and reduction of pyruvate. Lactate in this bacterium may arise through an endogenous metabolic mechanism via degradation of amino acids or via a lactate import system, which has also been shown to be upregulated in hemin excess. Other stressors including oxygen and growth in defined medium can also affect lactate metabolism in P. gingivalis. In Lewis et al. (50), hmuY and a lactate permease (PG1340) were both downregulated in micro-aerophilic conditions; and extracellular lactate was significantly reduced in anaerobiosis, while intracellular lactate was unaffected. In Moradali and Davey (51), exogenously added lactate to bovine serum albumin-based media downregulated virulence-associated genes including sprA (sov), ragA, and fimA, and significantly reduced bacterial growth. Thus, lactate flux is an important aspect of P. gingivalis physiology under different environmental conditions. It should be noted, however, that in the current study, the only variable between

 ${\sf mSystems}$

TABLE 7 Genes over-expressed in excess hemin conditions with differentially methylated cytosines (>1.5 LFC, >5% methylation difference, false discovery rate = 5%)^a

Locus tag	Gene	Gene Gene product	Contig	Gene	Gene	Strand	Gene Gene Strand Methylated Strand Distance	Strand L	Distance		DE analysis			DM analysis	.is	
	symbol	lc		start	pua	Expr.	end Expr. position meth. meth. baseMean LFC P-value	meth.	meth.	baseMean	LFC		Mean %	Mean %	Mean % methylation P-value	<i>P</i> -value
													methylation: LiH	methylation: LiH methylation: ExH difference	difference	
HMPREF1322_RS06180	'	Ppx/GppA family	Ppx/GppA family NZ_AJZS01000066.1	22201 23108	23108	1	22243		42	914.83	1.59	42 914.83 1.59 2.19E-12	10.21%	64.13%	53.91%	6.11E-07
		phosphatase														
HMPREF1322_RS06180	ı	Ppx/GppA family	NZ_AJZS01000066.1	22201	23108	ı	22943	+	742	914.83 1.59	1.59	2.19E-12	70.43%	31.90%	38.53%	2.21E-05
		phosphatase														

^oDE analysis, results from the differential expression analysis; Distance Meth, distance of the methylated position to the gene start site in base pairs, negative values indicate upstream location; DM analysis, results from the differential methylation analysis; ExH, growth in excess hemin; LFC, log 2 fold change; LiH, growth in limited hemin; Strand of the gene; Strand Meth, strand of the methylated position.

TABLE 8 Genes under-expressed in excess hemin conditions with differentially methylated cytosines (<-1.5 LFC, >5% methylation difference, false discovery rate = 5%)^a

	,	delle product	College	delle start	פבוע	5	Meniylated Stiania Distance									
s	symbol				puə	Expr.	position	meth.	meth.	baseMean	LFC	P-value	Mean %	Mean %	% methylation	P-value
													methylation: LiH n	methylation: ExH	difference	
HMPREF1322_RS00745	1	ABC transporter ATP-binding NZ_AJZS01000011.1	NZ_AJZS01000011.1	17886	19607	1	18653	+	792	3,619.54	-4.27	2.40E-57	4.65%	18.69%	14.04%	2.34E-05
		protein														
HMPREF1322_RS00730	ı	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	13730	+	-748	1,091.42	-3.38	5.01E-41	13.59%	58.15%	44.56%	1.13E-05
HMPREF1322_RS00730	ı	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	14106	+	-372	1,091.42	-3.38	5.01E-41	16.77%	47.36%	30.59%	7.45E-07
HMPREF1322_RS00730	ı	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	14542	+	64	1,091.42	-3.38	5.01E-41	15.67%	34.20%	18.53%	8.76E-06
HMPREF1322_RS00730	ı	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	14669	+	191	1,091.42	-3.38	5.01E-41	7.23%	19.84%	12.61%	1.28E-05
HMPREF1322_RS00730	ı	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	14693	+	215	1,091.42	-3.38	5.01E-41	14.07%	38.73%	24.67%	1.77E-05
HMPREF1322_RS00730	ı	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	14698	+	220	1,091.42	-3.38	5.01E-41	26.82%	44.78%	17.96%	7.90E-06
HMPREF1322_RS00730	ı	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	14706	+	228	1,091.42	-3.38	5.01E-41	2.91%	21.70%	18.79%	1.52E-05
HMPREF1322_RS00725	ı	Lactate utilization protein	NZ_AJZS01000011.1	13105	14472	+	12945	+	-160	911.64	-2.93	5.26E-38	5.18%	61.79%	56.61%	2.71E-06
HMPREF1322_RS00725	ı	Lactate utilization protein	NZ_AJZS01000011.1	13105	14472	+	12946	+	-159	911.64	-2.93	5.26E-38	4.71%	58.08%	53.37%	2.09E-06
HMPREF1322_RS00725	ı	Lactate utilization protein	NZ_AJZS01000011.1	13105	14472	+	13002	+	-103	911.64	-2.93	5.26E-38	3.76%	55.38%	51.62%	3.63E-06
HMPREF1322_RS00725	ı	Lactate utilization protein	NZ_AJZS01000011.1	13105	14472	+	13071	+	-34	911.64	-2.93	5.26E-38	4.20%	21.99%	17.79%	4.48E-06
HMPREF1322_RS00725	ı	Lactate utilization protein	NZ_AJZS01000011.1	13105	14472	+	13178	+	73	911.64	-2.93	5.26E-38	7.08%	60.16%	53.08%	2.24E-06
HMPREF1322_RS00725	ı	Lactate utilization protein	NZ_AJZS01000011.1	13105	14472	+	13240	+	135	911.64	-2.93	5.26E-38	8.76%	43.87%	35.12%	1.61E-06
HMPREF1322_RS00725	ı	Lactate utilization protein	NZ_AJZS01000011.1	13105	14472	+	13430	+	325	911.64	-2.93	5.26E-38	9.65%	38.76%	29.11%	2.55E-05
HMPREF1322_RS00725	ı	Lactate utilization protein	NZ_AJZS01000011.1	13105	14472	+	13730	+	625	911.64	-2.93	5.26E-38	13.59%	58.15%	44.56%	1.13E-05
HMPREF1322_RS00725	ı	Lactate utilization protein	NZ_AJZS01000011.1	13105	14472	+	14106	+	1001	911.64	-2.93	5.26E-38	16.77%	47.36%	30.59%	7.45E-07
HMPREF1322_RS00725	ı	Lactate utilization protein	NZ_AJZS01000011.1	13105	14472	+	14542	+	1437	911.64	-2.93	5.26E-38	15.67%	34.20%	18.53%	8.76E-06
HMPREF1322_RS00725	ı	Lactate utilization protein	NZ_AJZS01000011.1	13105	14472	+	14669	+	1564	911.64	-2.93	5.26E-38	7.23%	19.84%	12.61%	1.28E-05
HMPREF1322_RS00725	ı	Lactate utilization protein	NZ_AJZS01000011.1	13105	14472	+	14693	+	1588	911.64	-2.93	5.26E-38	14.07%	38.73%	24.67%	1.77E-05
HMPREF1322_RS00725	ı	Lactate utilization protein	NZ_AJZS01000011.1	13105	14472	+	14698	+	1593	911.64	-2.93	5.26E-38	26.82%	44.78%	17.96%	7.90E-06
HMPREF1322_RS00725	ı	Lactate utilization protein	NZ_AJZS01000011.1	13105	14472	+	14706	+	1601	911.64	-2.93	5.26E-38	2.91%	21.70%	18.79%	1.52E-05
HMPREF1322_RS00885	ı	U32 family peptidase	NZ_AJZS01000015.1	486	2393	ı	952	+	466	3,114.91	-3.09	3.14E-27	13.70%	22.02%	8.33%	6.03E-06
HMPREF1322_RS00860	htpG	Molecular chaperone HtpG	NZ_AJZS01000014.1	5016	7070	ı	5938	+	922	15,163.58	-2.87	2.96E-23	34.76%	52.63%	17.87%	2.45E-06
HMPREF1322_RS06465	ı	Hypothetical protein	NZ_AJZS01000069.1	2552	3754	ı	3434	ı	882	153,316.28	-2.35	1.18E-19	51.80%	41.48%	10.32%	1.97E-05
HMPREF1322_RS03650	ı	4-Alpha-glucanotransferase	NZ_AJZS01000038.1	2961	4847	ı	3558	ı	265	5,951.70	-2.22	5.69E-14	5.53%	95.22%	%69.68	4.16E-07
HMPREF1322_RS06460	ı	Transporter	NZ_AJZS01000069.1	784	2448	ı	3434	ı	2650	37,619.48	-2.01	1.02E-13	51.80%	41.48%	10.32%	1.97E-05
HMPREF1322_RS00740	ı	ABC transporter ATP-binding NZ_AJZS01000011.1	NZ_AJZS01000011.1	16133	17839	ı	18653	+	2520	7,059.72	-2.68	5.06E-10	4.65%	18.69%	14.04%	2.34E-05
		protein														
HMPREF1322_RS03860	ı	Histidinol phosphate	NZ_AJZS01000041.1	3824	4342	ı	4471	ı	647	15,144.78	-1.52	1.09E-09	17.52%	22.93%	5.41%	9.62E-06
		phosphatase														
HMPREF1322_RS00880	ı	DUF1661 domain-containing NZ_AJZS01000015.1	NZ_AJZS01000015.1	-	203	ı	952	+	951	129.52	-1.93	8.19E-07	13.70%	22.02%	8.33%	6.03E-06
		protein														

^aDE analysis, results from the differential expression analysis; Distance Meth, distance of the methylated position to the gene start site in base pairs, negative values indicate upstream location; DM analysis, results from the differential methylation analysis; ExH, growth in excess hemin; LFC, log2 fold change; LiH, growth in limited hemin; Strand of the gene; Strand Meth, strand of the methylated position.

Downloaded from https://journals.asm.org/journal/msystems on 26 January 2024 by 2.126.43.57.

TABLE 9 Differentially expressed genes with differentially methylated adenine sites and differentially methylated cytosines in excess hemin conditions (<-1.5 LFC, >5% methylation difference, false discovery rate = 5%%

This continue conti	20010	2002	toubour onother	Contin	Cono ctart	0000	Chrond	Potchidto M	Ctrond	Dietance		חב שכ	hveic				DM sasheris		
Protein Prot	Sin consort							meni yiqued		4	'		2	-	1		siskina ma	è	-
Production NEA/ASSO 000011 1305 1472 17366 1 1736 1 1736 1432 1 1736 1 1 1 1 1 1 1 1 1		symp	Į.			end	expr.	position	metn.	metn.		baseMea		<i>P</i> -value	Modificatio				<i>P</i> -value
Latter difference RZ_AZSO10000111 13105 1472 4 13945 4 -190 Under expt 91164 -239 5265-39 DNC 53794 5319																methylation		methylatior	_
- Lactive cultisation RLAZSO10000111 13105 14472 + 12945 + 1129 Under expg. 91164 - 229 5.285-39 DNC 5.19% S184 - Lactive cultisation RLAZSO10000111 13105 14472 + 13907 + 1294 Under expg. 91164 - 229 5.285-39 DNC 4.71% S184 - Lactive cultisation RLAZSO10000111 13105 14472 + 13907 + 1390 Under expg. 91164 - 229 5.285-39 DNC 7.09% S184 - Lactive cultisation RLAZSO10000111 13105 14472 + 13907 + 1390 Under expg. 91164 - 229 5.285-39 DNC 7.09% S184 - Lactive cultisation RLAZSO10000111 13105 14472 + 13907 + 1390 Under expg. 91164 - 229 5.285-39 DNC 7.09% S184 - Lactive cultisation RLAZSO10000111 13105 14472 + 13908 + 13908 + 1390 Under expg. 91164 - 229 5.285-39 DNC 7.09% S184 - Lactive cultisation RLAZSO10000111 13105 14472 + 13908 + 13908 Under expg. 91164 - 229 5.285-39 DNC 7.09% S184 - Lactive cultisation RLAZSO10000111 13105 14472 + 13908 H																HI	ExH	difference	
- Lacter utilization NZ_AZZSTOXOD11 13105 14472 + 13902 + -139 Uniderespt 91164 -229 5.265.36 DNC 4.71% 5310 potential protein NZ_AZZSTOXOD11 13105 14472 + 13002 + -130 Uniderespt 91164 -229 5.265.36 DNC 4.20% 2510 potential protein NZ_AZZSTOXOD11 13105 14472 + 13002 + -130 Uniderespt 91164 -229 5.265.36 DNC 4.20% 2510 potential numbers of the control of the contr	HMPREF1322_RS00725	ı	Lactate utilization	NZ_AJZS01000011.1		14472	+	12945	+	-160	Under expr		-2.93	5.26E-38	DMC	5.18%	61.79%	56.61%	2.71E-06
- Lacene utilization NZ_AZSO10000111 13105 14472 + 13900 + -159 Under egy. 91164 -239 5.266:38 DNC 4,71% 3850 protein - Lacene utilization NZ_AZSO10000111 13105 14472 + 13020 + -150 Under egy. 91164 -239 5.266:38 DNC 4,20% 2219 protein - Lacene utilization NZ_AZSO10000111 13105 14472 + 13230 + 13230 + 135 Under egy. 91164 -239 5.266:38 DNC 4,20% 2219 protein - Lacene utilization NZ_AZSO10000111 13105 14472 + 13240 + 135 Under egy. 91164 -239 5.266:38 DNC 6,84% 321 protein - Lacene utilization NZ_AZSO10000111 13105 14472 + 13240 + 135 Under egy. 91164 -239 5.266:38 DNC 8,76% 381 protein - Lacene utilization NZ_AZSO10000111 13105 14472 + 13240 + 135 Under egy. 91164 -239 5.266:38 DNC 1359% 381 protein - Lacene utilization NZ_AZSO10000111 13105 14472 + 13240 + 1300 Under egy. 91164 -239 5.266:38 DNC 1359% 381 protein - Lacene utilization NZ_AZSO10000111 13105 14472 + 14409 + 914 Under egy. 91164 -239 5.266:38 DNC 1359% 381 protein - Lacene utilization NZ_AZSO10000111 13105 14472 + 14409 + 914 Under egy. 91164 -239 5.266:38 DNC 1359% 381 protein - Lacene utilization NZ_AZSO10000111 13105 14472 + 14409 + 914 Under egy. 91164 -239 5.266:38 DNC 1359% 381 protein - Lacene utilization NZ_AZSO10000111 13105 14472 + 14200 + 1000 Under egy. 91164 -239 5.266:38 DNA 1469% 381 protein - Lacene utilization NZ_AZSO10000111 13105 14472 + 14200 + 1000 Under egy. 91164 -239 5.266:38 DNA 1469% 381 protein - Lacene utilization NZ_AZSO1000011 13105 14472 + 14200 + 1000 Under egy. 91164 -239 5.266:38 DNA 1269% 9184 protein - Lacene utilization NZ_AZSO1000011 13105 14472 + 14200 + 1000 Under egy. 91164 -239 5.266:38 DNA 1269% 9184 protein - Lacene utilization NZ_AZSO1000011 13105 14472 + 14200 + 1000 Under egy. 91164 -239 5.266:38 DNA 1269% 9184 protein - Lacene utilization NZ_AZSO1000011 13105 14472 + 14200 + 1000 Under egy. 91164 -239 5.266:38 DNA 1269% 9184 protein - Lacene utilization NZ_AZSO1000011 13105 14472 + 14200 + 1000 Under egy. 91164 -239 5.266:38 DNA 1269% 9184 protein			protein								:				!				
- Lactbe utilization NZ_ALZGO10000111 13105 14472 + 13070 + -130 Under expt. 91164 -229 5.265-39 DMC 3.76% 3.56 protein protein control of the control of th	HMPREF1322_RS00725	I	Lactate utilization	NZ_AJZS01000011.1	13105	14472	+	12946	+	-159	Underexpi		-2.93	5.26E-38	DWC	4.71%	58.08%	53.37%	2.09E-06
- Lactes utilization NZ_ALZSO1000111 13105 14472 + 13071 + -34 Under eignt 91164 -223 5265-38 DMC 4.20% 521 protein protein control of the co			protein																
- Lectute utilization NZ_AZZ5010000111 13105 14472 + 13971 + -34 Under expr. 91164 -239 5.26€-38 DMC 4.20% 2019 protein control of the contro	HMPREF1322_RS00725	I	Lactate utilization	NZ_AJZS01000011.1	13105	14472	+	13002	+	-103	Under expr		-2.93	5.26E-38	DMC	3.76%	55.38%	51.62%	3.63E-06
- Lectre efficiation NZ_AZS010000111 13105 14472 + 13778 + -34 Under expc 91154 -229 5.265-38 DMC 4.20% 21154 Depote 1 protein - Lectre efficiation NZ_AZS010000111 13105 14472 + 13236 + 133 Under expc 91154 -229 5.265-38 DMC 6.89% 220 protein - Lectre efficiation NZ_AZS010000111 13105 14472 + 13230 + 135 Under expc 91154 -229 5.265-38 DMC 6.89% 232 DMC 9106% 240 protein - Lectre efficiation NZ_AZS010000111 13105 14472 + 13230 + 132 Under expc 91154 -229 5.265-38 DMC 9155% 383 DMC 9106% - Lectre efficiation NZ_AZS010000111 13105 14472 + 13230 + 13240			protein																
Decinic continue NZ.AZSO10000111 13103 14472 + 113286 + 131 Underegic 91164 -233 526538 DMC 708% 628%	HMPREF1322_RS00725	1	Lactate utilization	NZ_AJZS01000011.1	13105	14472	+	13071	+	-34	Under expr		-2.93	5.26E-38	DMC	4.20%	21.99%	17.79%	4.48E-06
- Lactine utilization NZ_AZSO10000111 13105 14472 + 13236 + 131 Under egg, 91164 -233 5.265-38 DMC 6.84% S20 protein a protein NZ_AZSO10000111 13105 14472 + 13230 + 133 Under egg, 91164 -233 5.265-38 DMC 6.84% S20			protein																
Lectre utilization NZ_AZSO10000111 13105 14472 + 132.6 + 131 Under expr. 911.64 2.293 5.26E-38 DMA 6.64% 5.24 - Lectre utilization NZ_AZSO10000111 13105 14472 + 13240 + 135 Under expr. 911.64 -2.93 5.26E-38 DMA 8.76% 483 - Lectre utilization NZ_AZSO10000111 13105 14472 + 13290 + 479 Under expr. 911.64 -2.93 5.26E-38 DMA 2,40% 381 - Lectre utilization NZ_AZSO10000111 13105 14472 + 13594 + 479 Under expr. 911.64 -2.93 5.26E-38 DMA 2,40% 381 - Lectre utilization NZ_AZSO10000111 13105 14472 + 13985 + 623 Under expr. 911.64 -2.93 5.26E-38 DMA 3,67% 9,67% 9,7% - Lectre utilization NZ_AZSO10000111 1310	HMPREF1322_RS00725	I	Lactate utilization	NZ_AJZS01000011.1	13105	14472	+	13178	+	73	Under expr		-2.93	5.26E-38	DMC	7.08%	60.16%	53.08%	2.24E-06
- Lactae utilization NZ_AZSO10000111 13105 14472 + 13236 + 131 Under expt. 91164 - 293 5.26E-38 DMA 684% 522 Protein - Lactae utilization NZ_AZSO10000111 13105 14472 + 13540 + 13540 H 479 Under expt. 91164 - 293 5.26E-38 DMA 684% 538. - Lactae utilization NZ_AZSO10000111 13105 14472 + 13540 H 479 Under expt. 91164 - 293 5.26E-38 DMA 685% 144 - Lactae utilization NZ_AZSO10000111 13105 14472 + 13540 H 479 Under expt. 91164 - 293 5.26E-38 DMA 788% 1319 - Lactae utilization NZ_AZSO10000111 13105 14472 + 13540 H 479 Under expt. 91164 - 293 5.26E-38 DMA 383% 371 - Lactae utilization NZ_AZSO10000111 13105 14472 + 14010 H 1320 Under expt. 91164 - 293 5.26E-38 DMA 383% 371 - Lactae utilization NZ_AZSO10000111 13105 14472 + 14010 H 1320 Under expt. 91164 - 293 5.26E-38 DMA 383% 371 - Lactae utilization NZ_AZSO10000111 13105 14472 + 14010 H 1402 H 1001 Under expt. 91164 - 293 5.26E-38 DMA 5.26F-38 DMA 5.26			protein																
- Lacte utilization NZ_AZS01000011.1 13105 14472 + 13240 + 1325 Under expr. 91164 -293 5.26E-38 DMC 8/2% 838 Lacte utilization NZ_AZS01000011.1 13105 14472 + 13430 + 325 Under expr. 91164 -293 5.26E-38 DMA 24/3% 965% 38 Lacte utilization NZ_AZS01000011.1 13105 14472 + 13395 + 479 Under expr. 91164 -293 5.26E-38 DMA 24/3% 91400 DMA 24/2% 91600 DMA 24/3% 916000 DMA 24/3% 91600 DMA 24/3% 916000 DMA 24/3% 9160000 DMA 24/3% 9160000 DMA 24/3% 916000 DMA 24/3% 9160000 DMA 24/3% 9160000 DMA 24/3% 9160000 DMA 24/3% 9160000 DMA 24/3% 91600000 DMA 24/3% 91600000 DMA 24/3% 916000000000000000000000000000000000000	HMPREF1322_RS00725	ı	Lactate utilization	NZ_AJZS01000011.1	13105	14472	+	13236	+	131	Under expr		-2.93	5.26E-38	DMA	6.84%	52.42%	45.58%	5.83E-06
Processor defination NZ_AZS01000011, 13105 14472 + 13400 + 1350 + 13			protein																
- Lactate utilization NZ_AZS01000011, 13105 14472 + 13584 + 479 Under expr. 91164 -293 5.26E-38 DMC 965% 38. - Lactate utilization NZ_AZS01000011, 13105 14472 + 13584 + 479 Under expr. 91164 -293 5.26E-38 DMC 13.59% 144	HMPREF1322_RS00725	ı	Lactate utilization	NZ_AJZS01000011.1	13105	14472	+	13240	+	135	Under expr		-2.93	5.26E-38	DMC	8.76%	43.87%	35.12%	1.61E-06
- Lactate utilization NZ_AZS01000011.1 13105 14472 + 13430 + 479 Under expr. 911.64 -2.93 5.26E-38 DMA 9.65% 383. Protein - Lactate utilization NZ_AZS01000011.1 13105 14472 + 13730 + 625 Under expr. 911.64 -2.93 5.26E-38 DMA 13.59% 14.8 - Lactate utilization NZ_AZS01000011.1 13105 14472 + 14019 + 14019			protein																
- Lactate utilization NZ_AIZS01000011.1 13105 14472 + 13584 + 479 Under expr. 91164 -293 5.26E-38 DMA 240% 144 - Lactate utilization NZ_AIZS01000011.1 13105 14472 + 13730 + 623 Under expr. 91164 -293 5.26E-38 DMA 1359% 5.81 - Lactate utilization NZ_AIZS01000011.1 13105 14472 + 13965 + 860 Under expr. 91164 -293 5.26E-38 DMA 1359% 5.36 - Lactate utilization NZ_AIZS01000011.1 13105 14472 + 14019 + 914 Under expr. 91164 -293 5.26E-38 DMA 148% 34.3 - Lactate utilization NZ_AIZS01000011.1 13105 14472 + 1400 + 1091 Under expr. 91164 -293 5.26E-38 DMA 148% 178 - Lactate utilization NZ_AIZS010000011.1 13105	HMPREF1322_RS00725	1	Lactate utilization	NZ_AJZS01000011.1	13105	14472	+	13430	+	325	Under expr		-2.93	5.26E-38	DMC	9.65%	38.76%	29.11%	2.55E-05
- Lactate utilization NZ_ANZSO1000011.1 13105 14472 + 13584 + 479 Under expr. 91164 -2.93 5.26E-38 DMA 240% 144 - Lactate utilization NZ_ANZSO1000011.1 13105 14472 + 14019 + 14019 Under expr. 91164 -2.93 5.26E-38 DMA 3433% 373 - Lactate utilization NZ_ANZSO1000011.1 13105 14472 + 14019 + 14019 Under expr. 91164 -2.93 5.26E-38 DMA 148% 343. - Lactate utilization NZ_ANZSO1000011.1 13105 14472 + 14019 H 1001 Under expr. 91164 -2.93 5.26E-38 DMA 148% 343. - Lactate utilization NZ_ANZSO1000011.1 13105 14472 + 14019 H 1001 Under expr. 91164 -2.93 5.26E-38 DMA 5.29% 183. - Lactate utilization NZ_ANZSO1000011.1 13105 14472 + 14324 + 14324 H 1239 Under expr. 91164 -2.93 5.26E-38 DMA 5.243% 193. - Lactate utilization NZ_ANZSO1000011.1 13105 14472 + 14324 H 14324 H 1239 Under expr. 91164 -2.93 5.26E-38 DMA 1.76% 1737			protein																
protein Lactate utilization NZ_AZS01000011.1 13105 14472 + 13730 + 625 Under expr. 91164 -2.93 5.26E-38 DMC 13.59% 58. protein - Lactate utilization NZ_AZS01000011.1 13105 14472 + 14019 + 914 Under expr. 91164 -2.93 5.26E-38 DMA 3.83% 37.5 - Lactate utilization NZ_AZS01000011.1 13105 14472 + 14019 + 914 Under expr. 91164 -2.93 5.26E-38 DMA 148% 34.7 - Lactate utilization NZ_AZS01000011.1 13105 14472 + 14019 + 914 Under expr. 91164 -2.93 5.26E-38 DMA 3.83% 37.8 - Lactate utilization NZ_AZS01000011.1 13105 14472 + 14200 + 1094 -2.93 5.26E-38 DMA 2.43% 175 - Lactat	HMPREF1322_RS00725	ı	Lactate utilization	NZ_AJZS01000011.1	13105	14472	+	13584	+	479	Under expr		-2.93	5.26E-38	DMA	2.40%	14.66%	12.25%	5.18E-07
- Lactate utilization NZ_AZS01000011.1 13105 14472 + 13965 + 625 Under expr. 911.64 -2.93 5.26E-38 DMA 3.83% 37.8 protein - Lactate utilization NZ_AZS01000011.1 13105 14472 + 14019 + 14010 Under expr. 911.64 -2.93 5.26E-38 DMA 1.48% 34.3 protein - Lactate utilization NZ_AZS01000011.1 13105 14472 + 14019 + 14010 Under expr. 911.64 -2.93 5.26E-38 DMA 1.48% 34.3 protein - Lactate utilization NZ_AZS01000011.1 13105 14472 + 14010 H 1001 Under expr. 911.64 -2.93 5.26E-38 DMA 5.92% 18.1 protein - Lactate utilization NZ_AZS01000011.1 13105 14472 + 14320 H 14320 H 1001 Under expr. 911.64 -2.93 5.26E-38 DMA 5.92% 18.1 protein - Lactate utilization NZ_AZS01000011.1 13105 14472 + 14320 H 14320 H 1005 Under expr. 911.64 -2.93 5.26E-38 DMA 2.43% 19.2 protein - Lactate utilization NZ_AZS01000011.1 13105 14472 H 14320 H 14320 H 1210 Under expr. 911.64 -2.93 5.26E-38 DMA 2.43% 19.2 protein - Lactate utilization NZ_AZS01000011.1 13105 14472 H 14320 H 14320 H 13210 Under expr. 911.64 -2.93 5.26E-38 DMA 9.97% 19.3 protein - Lactate utilization NZ_AZS01000011.1 13105 14472 H 14487 H 14320 H 1210 Under expr. 911.64 -2.93 5.26E-38 DMA 9.97% 19.3 protein - Lactate utilization NZ_AZS01000011.1 13105 14472 H 14487 H 1320 Under expr. 911.64 -2.93 5.26E-38 DMA 9.97% 19.3 protein			protein																
- Lactate utilization NZ_AZS01000011.1 13105 14472 + 13965 + 860 Under expr. 91164 -2293 5.26E-38 DMA 3.83% 37.8 provein - Lactate utilization NZ_AZS01000011.1 13105 14472 + 14019 + 914 Under expr. 91164 -2.293 5.26E-38 DMA 1.48% 34.2 provein - Lactate utilization NZ_AZS01000011.1 13105 14472 + 14106 + 1001 Under expr. 91164 -2.293 5.26E-38 DMA 5.92% 18.1 provein - Lactate utilization NZ_AZS01000011.1 13105 14472 + 14320 + 14323 + 1218 Under expr. 91164 -2.293 5.26E-38 DMA 5.92% 19.8 provein - Lactate utilization NZ_AZS01000011.1 13105 14472 + 14323 + 1218 Under expr. 91164 -2.293 5.26E-38 DMA 2.43% 19.8 provein - Lactate utilization NZ_AZS01000011.1 13105 14472 + 14324 + 1219 Under expr. 91164 -2.293 5.26E-38 DMA 1.76% 1775 provein - Lactate utilization NZ_AZS01000011.1 13105 14472 + 14324 + 12324 Under expr. 91164 -2.293 5.26E-38 DMA 1.76% 1775 provein - Lactate utilization NZ_AZS01000011.1 13105 14472 + 14487 + 1382 Under expr. 91164 -2.293 5.26E-38 DMA 0.97% 19.9 provein	HMPREF1322_RS00725	1	Lactate utilization	NZ_AJZS01000011.1	13105	14472	+	13730	+	625	Under expr		-2.93	5.26E-38	DMC	13.59%	58.15%	44.56%	1.13E-05
- Lactate utilization NZ_AJZS01000011.1 13105 14472 + 13965 + 860 Under expr. 911.64 - 2.93 5.26E-38 DMA 3.83% 37.8 Protein - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14019 + 914 Under expr. 911.64 - 2.93 5.26E-38 DMA 1.48% 34.1 - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14019 + 1001 Under expr. 911.64 - 2.93 5.26E-38 DMA 5.92% 181. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14323 + 14323 + 1218 Under expr. 911.64 - 2.93 5.26E-38 DMA 2.43% 192. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14323 + 14324 + 1230 Under expr. 911.64 - 2.93 5.26E-38 DMA 2.43% 192. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14324 + 14324 + 1382 Under expr. 911.64 - 2.93 5.26E-38 DMA 0.97% 192. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14324 + 14324 + 1382 Under expr. 911.64 - 2.93 5.26E-38 DMA 0.97% 192. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14324 + 14324 + 1382 Under expr. 911.64 - 2.93 5.26E-38 DMA 0.97% 192. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14487 + 14824 + 1382 Under expr. 911.64 - 2.93 5.26E-38 DMA 0.97% 192. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14487 + 14324 + 1382 Under expr. 911.64 - 2.93 5.26E-38 DMA 0.97% 192. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14487 + 14824 + 1382 Under expr. 911.64 - 2.93 5.26E-38 DMA 0.97% 192. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14487 + 14824 + 1382 Under expr. 911.64 - 2.93 5.26E-38 DMA 0.97% 192. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14487 + 14824 + 1382 Under expr. 911.64 - 2.93 5.26E-38 DMA 0.97% 192. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14487 + 14824 + 1382 Under expr. 911.64 - 2.93 5.26E-38 DMA 0.97% 193. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14487 + 14824 + 1382 Under expr. 911.64 - 2.93 5.26E-38 DMA 0.97% 193. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14487 + 14324 + 1382 Under expr. 911.64 - 2.93 5.26E-38 DMA 0.97% 193. - Lactate utilization NZ_AJZS010			protein																
protein 472 14019 4 914 Under expr. 911.64 -2.93 5.26E-38 DMA 148% 34,2 - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14106 + 1001 Under expr. 911.64 -2.93 5.26E-38 DMA 16.77% 47.72 - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14200 + 1095 Under expr. 911.64 -2.93 5.26E-38 DMA 5.92% 188. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14323 + 1218 Under expr. 911.64 -2.93 5.26E-38 DMA 2.43% 198. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14324 + 1219 Under expr. 911.64 -2.93 5.26E-38 DMA 1,76% 17.7 - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14324 + 12	HMPREF1322 RS00725	1	Lactate utilization	NZ AJZS01000011.1	13105	14472	+	13965	+	860	Under expr		-2.93	5.26E-38	DMA	3.83%	37.85%	34.02%	4.16E-06
- Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14019 + 914 Under expr. 911.64 -2.93 5.26E-38 DMA 148% 34. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14200 + 1001 Under expr. 911.64 -2.93 5.26E-38 DMA 5.92% 188. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14324 + 114324 + 1219 Under expr. 911.64 -2.93 5.26E-38 DMA 2.43% 198. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14324 + 14324 + 1219 Under expr. 911.64 -2.93 5.26E-38 DMA 2.43% 173. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14487 + 14487 + 1382 Under expr. 911.64 -2.93 5.26E-38 DMA 1.76% 173. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14487 + 14887 + 1382 Under expr. 911.64 -2.93 5.26E-38 DMA 0.97% 193. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14487 + 14887 + 1382 Under expr. 911.64 -2.93 5.26E-38 DMA 0.97% 193. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14487 + 14887 + 1382 Under expr. 911.64 -2.93 5.26E-38 DMA 0.97% 193.			protein)	:							ì						
– Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14106 + 1001 Under expr. 911.64 –2.93 5.26E-38 DMC 16.77% 47.77 – Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14200 + 1095 Under expr. 911.64 –2.93 5.26E-38 DMA 5.92% 188. – Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14323 + 1218 Under expr. 911.64 –2.93 5.26E-38 DMA 2.43% 198. – Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14324 + 1219 Under expr. 911.64 –2.93 5.26E-38 DMA 1,75% protein - Lactate utilization NZ_AJZS01000011.1 13105 14427 + 14487 + 1219 Under expr. 911.64 –2.93 5.26E-38 DMA 1,75% - Lactate utilization NZ_AJZS01000011.1 <td< td=""><td>HMPREF1322_RS00725</td><td>I</td><td>Lactate utilization</td><td>NZ_AJZS01000011.1</td><td>13105</td><td>14472</td><td>+</td><td>14019</td><td>+</td><td>914</td><td>Under expr</td><td></td><td>-2.93</td><td>5.26E-38</td><td>DMA</td><td>1.48%</td><td>34.21%</td><td>32.73%</td><td>1.48E-05</td></td<>	HMPREF1322_RS00725	I	Lactate utilization	NZ_AJZS01000011.1	13105	14472	+	14019	+	914	Under expr		-2.93	5.26E-38	DMA	1.48%	34.21%	32.73%	1.48E-05
- Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14106 + 1001 Under expr. 911.64 -2.93 5.26E-38 DMC 16.77% 47.2 protein - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14323 + 1210 Under expr. 911.64 -2.93 5.26E-38 DMA 5.92% 188. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14324 + 1219 Under expr. 911.64 -2.93 5.26E-38 DMA 2.43% 173. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14324 + 1219 Under expr. 911.64 -2.93 5.26E-38 DMA 1.76% 173. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14487 + 14487 + 1310 Under expr. 911.64 -2.93 5.26E-38 DMA 0.97% 193. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14487 + 14487 + 1310 Under expr. 911.64 -2.93 5.26E-38 DMA 0.97% 193. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14487 + 14487 + 1310 Under expr. 911.64 -2.93 5.26E-38 DMA 0.97% 193. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14487 + 14487 + 1310 Under expr. 911.64 -2.93 5.26E-38 DMA 0.97% 193. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14487 + 14487 + 1310 Under expr. 911.64 -2.93 5.26E-38 DMA 0.97% 193. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14487 + 14487 + 1310 Under expr. 911.64 -2.93 5.26E-38 DMA 0.97% 193. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14487 + 1382 Under expr. 911.64 -2.93 5.26E-38 DMA 0.97% 193. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14487 + 1382 Under expr. 911.64 -2.93 5.26E-38 DMA 0.97% 193. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14487 + 1382 Under expr. 911.64 -2.93 5.26E-38 DMA 0.97% 193. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14487 + 1382 Under expr. 911.64 -2.93 5.26E-38 DMA 0.97% 193. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14487 + 14487 + 1382 Under expr. 911.64 -2.93 5.26E-38 DMA 0.97% 193. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14487 + 14487 + 1382 Under expr. 911.64 -2.93 5.26E-38 DMA 0.97% 193. - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14487 + 14487 + 1382 Under expr			protein																
protein Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14200 + 1095 Under expr. 911.64 -2.93 5.26E-38 DMA 5.92% 18: - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14323 + 1218 Under expr. 911.64 -2.93 5.26E-38 DMA 2.43% 19: - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14324 + 1219 Under expr. 911.64 -2.93 5.26E-38 DMA 1,75% 17: - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14487 + 1219 Under expr. 911.64 -2.93 5.26E-38 DMA 1,75% - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14487 + 1382 Under expr. 911.64 -2.93 5.26E-38 DMA 0,97% 195	HMPREF1322_RS00725	I	Lactate utilization	NZ_AJZS01000011.1	13105	14472	+	14106	+	1001	Under expr		-2.93	5.26E-38	DMC	16.77%	47.36%	30.59%	7.45E-07
- Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14200 + 1095 Under expr. 911.64 -2.93 5.26E-38 DMA 5.92% 18.1 Protein - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14323 + 1218 Under expr. 911.64 -2.93 5.26E-38 DMA 2.43% 19.8 Protein - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14487 + 14487 + 1382 Under expr. 911.64 -2.93 5.26E-38 DMA 1.76% 17.1 Protein - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14487 + 14487 + 1382 Under expr. 911.64 -2.93 5.26E-38 DMA 0.97% 19.3 Protein - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14487 + 14487 + 1382 Under expr. 911.64 -2.93 5.26E-38 DMA 0.97% 19.3 Protein			protein																
- Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14323 + 1218 Under expr. 911.64 -2.93 5.26E-38 DMA 2.43% 198 Protein - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14324 + 1219 Under expr. 911.64 -2.93 5.26E-38 DMA 1,76% 17.7 - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14487 + 1382 Under expr. 911.64 -2.93 5.26E-38 DMA 0.97% 195.	HMPREF1322_RS00725	ı	Lactate utilization	NZ_AJZS01000011.1	13105	14472	+	14200	+	1095	Under expr		-2.93		DMA	5.92%	18.54%	12.62%	8.66E-06
- Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14323 + 1218 Under expr. 911,64 -2.93 5.26E-38 DMA 2.43% 198. protein - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14324 + 1219 Under expr. 911,64 -2.93 5.26E-38 DMA 1,76% 17.7 protein - Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14487 + 1382 Under expr. 911,64 -2.93 5.26E-38 DMA 0.97% 193.			protein																
protein Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14324 + 1219 Under expr. 911.64 -2.93 5.26E-38 DMA 1.76% 17: protein Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14487 + 1382 Under expr. 911.64 -2.93 5.26E-38 DMA 0.97% 19:	HMPREF1322_RS00725	ı	Lactate utilization	NZ_AJZS01000011.1	13105	14472	+	14323	+	1218	Under expr		-2.93	5.26E-38	DMA	2.43%	19.81%	17.38%	1.65E-05
- Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14324 + 1219 Under expr. 911.64 -2.93 5.26E-38 DMA 1.76% 17.7 protein			protein																
protein – Lactate utilization NZ_AJZS01000011.1 13105 14472 + 14487 + 1382 Under expr. 911.64 –2.93 5.26E-38 DMA 0.97% 19.5 protein	HMPREF1322_RS00725	I	Lactate utilization	NZ_AJZS01000011.1	13105	14472	+	14324	+	1219	Under expr		-2.93	5.26E-38	DMA	1.76%	17.10%	15.34%	3.75E-06
- Lactate utilization NZ_AJZ501000011.1 13105 14472 + 14487 + 1382 Under expr. 911.64 -2.93 5.26E-38 DMA 0.97% 19.: protein			protein																
	HMPREF1322_RS00725	I	Lactate utilization	NZ_AJZS01000011.1	13105	14472	+	14487	+	1382	Under expr		-2.93	5.26E-38	DMA	0.97%	19.32%	18.35%	2.62E-06
(Continued on 1			protein																
																	(Cont	inued on r	ext page)

Downloaded from https://journals.asm.org/journal/msystems on 26 January 2024 by 2.126.43.57.

TABLE 9 Differentially expressed genes with differentially methylated adenine sites and differentially methylated cytosines in excess hemin conditions (LFC, >5% methylation difference, false discovery rate = 5%) (Continued)

Locus tag	Gene	Gene Gene product	Contig	Gene start	Gene	Strand	Strand Methylated	Strand	Distance		DE analysis	ysis				DM analysis		
	symbol	- 0			end	expr.	position	meth.	meth.	Direction	baseMean	LFC	P-value	Modification	Mean %	Mean %	%	P-value
															methylation:	methylation:	methylation	
															H	ExH	difference	
HMPREF1322_RS00725	1	Lactate utilization	NZ_AJZS01000011.1	13105	14472	+	14511	+	1406	Under expr.	911.64	-2.93	5.26E-38	DMA	4.96%	46.35%	41.39%	3.60E-06
		protein																
HMPREF1322_RS00725	I	Lactate utilization	NZ_AJZS01000011.1	13105	14472	+	14512	+	1407	Under expr.	911.64	-2.93	5.26E-38	DMA	5.03%	41.65%	36.62%	1.56E-05
		protein																
HMPREF1322_RS00725	I	Lactate utilization	NZ_AJZS01000011.1	13105	14472	+	14542	+	1437	Under expr.	911.64	-2.93	5.26E-38	DMC	15.67%	34.20%	18.53%	8.76E-06
		protein																
HMPREF1322_RS00725	ı	Lactate utilization	NZ_AJZS01000011.1	13105	14472	+	14644	+	1539	Under expr.	911.64	-2.93	5.26E-38	DMA	5.20%	29.07%	23.87%	4.28E-06
		protein																
HMPREF1322_RS00725	I	Lactate utilization	NZ_AJZS01000011.1	13105	14472	+	14669	+	1564	Under expr.	911.64	-2.93	5.26E-38	DMC	7.23%	19.84%	12.61%	1.28E-05
		protein																
HMPREF1322_RS00725	ı	Lactate utilization	NZ_AJZS01000011.1	13105	14472	+	14693	+	1588	Under expr.	911.64	-2.93	5.26E-38	DMC	14.07%	38.73%	24.67%	1.77E-05
		protein																
HMPREF1322_RS00725	I	Lactate utilization	NZ_AJZS01000011.1	13105	14472	+	14698	+	1593	Under expr.	911.64	-2.93	5.26E-38	DMC	26.82%	44.78%	17.96%	7.90E-06
		protein																
HMPREF1322_RS00725	1	Lactate utilization	NZ_AJZS01000011.1	13105	14472	+	14706	+	1601	Under expr.	911.64	-2.93	5.26E-38	DMC	2.91%	21.70%	18.79%	1.52E-05
		protein																
HMPREF1322_RS00725	1	actate utilization	NZ_AJZS01000011.1	13105	14472	+	14744	+	1639	Under expr.	911.64	-2.93	5.26E-38	DMA	2.00%	28.52%	26.52%	1.52E-06
		protein																
HMPREF1322_RS00725	1	Lactate utilization	NZ_AJZS01000011.1	13105	14472	+	15471	+	2366	Under expr.	911.64	-2.93	5.26E-38	DMA	7.97%	28.75%	20.78%	1.11E-05
		protein																
HMPREF1322_RS00730	I	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	13584	+	-894	Under expr.	1,091.42	-3.38	5.01E-41	DMA	2.40%	14.66%	12.25%	5.18E-07
HMPREF1322_RS00730	I	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	13730	+	-748	Under expr.	1,091.42	-3.38	5.01E-41	DMC	13.59%	58.15%	44.56%	1.13E-05
HMPREF1322_RS00730	I	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	13965	+	-513	Under expr.	1,091.42	-3.38	5.01E-41	DMA	3.83%	37.85%	34.02%	4.16E-06
HMPREF1322_RS00730	I	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	14019	+	-459	Under expr.	1,091.42	-3.38	5.01E-41	DMA	1.48%	34.21%	32.73%	1.48E-05
HMPREF1322_RS00730	I	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	14106	+	-372	Under expr.	1,091.42	-3.38	5.01E-41	DMC	16.77%	47.36%	30.59%	7.45E-07
HMPREF1322_RS00730	1	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	14200	+	-278	Under expr.	1,091.42	-3.38	5.01E-41	DMA	5.92%	18.54%	12.62%	8.66E-06
HMPREF1322_RS00730	I	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	14323	+	-155	Under expr.	1,091.42	-3.38	5.01E-41	DMA	2.43%	19.81%	17.38%	1.65E-05
HMPREF1322_RS00730	I	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	14324	+	-154	Under expr.	1,091.42	-3.38	5.01E-41	DMA	1.76%	17.10%	15.34%	3.75E-06
HMPREF1322_RS00730	I	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	14487	+	6	Under expr.	1,091.42	-3.38	5.01E-41	DMA	%26.0	19.32%	18.35%	2.62E-06
HMPREF1322_RS00730	I	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	14511	+	33	Under expr.	1,091.42	-3.38	5.01E-41	DMA	4.96%	46.35%	41.39%	3.60E-06
HMPREF1322_RS00730	I	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	14512	+	34	Under expr.	1,091.42	-3.38	5.01E-41	DMA	5.03%	41.65%	36.62%	1.56E-05
HMPREF1322_RS00730	I	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	14542	+	64	Under expr.	1,091.42	-3.38	5.01E-41	DMC	15.67%	34.20%	18.53%	8.76E-06
HMPREF1322_RS00730	I	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	14644	+	166	Under expr.	1,091.42	-3.38	5.01E-41	DMA	5.20%	29.07%	23.87%	4.28E-06
HMPREF1322_RS00730	I	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	14669	+	191	Under expr.	1,091.42	-3.38	5.01E-41	DMC	7.23%	19.84%	12.61%	1.28E-05
																(Cont	(Continued on next page)	ext page)

Downloaded from https://journals.asm.org/journal/msystems on 26 January 2024 by 2.126.43.57.

mSystems

TABLE 9 Differentially expressed genes with differentially methylated adenine sites and differentially methylated cytosines in excess hemin conditions (LFC, >5% methylation difference, false discovery rate = 5%) (Continued)

			0															
	symbol				puə	expr.	position	meth.	meth.	Direction	baseMean	LFC	P-value	Modification	Mean %	Mean %	%	<i>P</i> -value
															methylation:	methylation:	methylation	_
															H	ExH	difference	
HMPREF1322_RS00730	ı	Hypothetical protein	Hypothetical protein NZ_AJZS01000011.1	14478	15062	+	14693	+	215	Under expr.	1,091.42	-3.38	5.01E-41	DMC	14.07%	38.73%	24.67%	1.77E-05
HMPREF1322_RS00730	ı	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	14698	+	220	Under expr.	1,091.42	-3.38	5.01E-41	DMC	26.82%	44.78%	17.96%	7.90E-06
HMPREF1322_RS00730	I	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	14706	+	228	Under expr.	1,091.42	-3.38	5.01E-41	DMC	2.91%	21.70%	18.79%	1.52E-05
HMPREF1322_RS00730	ı	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	14744	+	266	Under expr.	1,091.42	-3.38	5.01E-41	DMA	2.00%	28.52%	26.52%	1.52E-06
HMPREF1322_RS00730	ı	Hypothetical protein	NZ_AJZS01000011.1	14478	15062	+	15471	+	993	Under expr.	1,091.42	-3.38	5.01E-41	DMA	7.97%	28.75%	20.78%	1.11E-05
HMPREF1322_RS00740	ı	ABC transporter	NZ_AJZS01000011.1	16133	17839	ı	15471	+	-662	Under expr.	7,059.72	-2.68	5.06E-10	DMA	7.97%	28.75%	20.78%	1.11E-05
		ATP-binding protein	_															
HMPREF1322_RS00740	ı	ABC transporter	NZ_AJZS01000011.1	16133	17839	ı	17614	+	1481	Under expr.	7,059.72	-2.68	5.06E-10	DMA	2.76%	16.42%	13.66%	1.15E-05
		ATP-binding protein	_															
HMPREF1322_RS00740	ı	ABC transporter	NZ_AJZS01000011.1	16133	17839	ı	18653	+	2520	Under expr.	7,059.72	-2.68	5.06E-10	DMC	4.65%	18.69%	14.04%	2.34E-05
		ATP-binding protein	_															
HMPREF1322_RS00745	ı	ABC transporter	NZ_AJZS01000011.1	17886	19607	ı	17614	+	-272	Under expr.	3,619.54	-4.27	2.40E-57	DMA	2.76%	16.42%	13.66%	1.15E-05
		ATP-binding protein	_															
HMPREF1322_RS00745	ı	ABC transporter	NZ_AJZS01000011.1	17886	19607	ı	18653	+	167	Under expr.	3,619.54	-4.27	2.40E-57	DMC	4.65%	18.69%	14.04%	2.34E-05
		ATP-binding protein	_															
HMPREF1322_RS00745	I	ABC transporter	NZ_AJZS01000011.1	17886	19607	ı	19392	+	1506	Under expr.	3,619.54	-4.27	2.40E-57	DMA	7.54%	25.19%	17.66%	1.14E-05
		ATP-binding protein	_															
HMPREF1322_RS03650	ı	4-Alpha-glucanotrans	4-Alpha-glucanotrans- NZ_AJZS01000038.1	2961	4847	ı	3558	ı	597	Under expr.	5,951.7	-2.22	5.69E-14	DMC	5.53%	95.22%	89.69%	4.16E-07
		ferase																
HMPREF1322_RS03650	ı	4-Alpha-glucanotrans	4-Alpha-glucanotrans- NZ_AJZS01000038.1	2961	4847	ı	3559	ı	298	Under expr.	5,951.7	-2.22	5.69E-14	DMA	4.43%	89.64%	85.21%	7.67E-08
		ferase																
HMPREF1322_RS03650	ı	4-Alpha-glucanotrans	4-Alpha-glucanotrans- NZ_AJZS01000038.1	2961	4847	ı	3560	ı	299	Under expr.	5,951.7	-2.22	5.69E-14	DMA	1.45%	86.22%	84.77%	5.31E-06
		ferase																
HMPREF1322_RS06180	I	Ppx/GppA family	NZ_AJZS01000066.1	22201	23108	ı	22242	ı	41	Over expr.	914.83	1.59	2.19E-12	DMA	15.95%	%08'96	80.86%	3.66E-07
		phosphatase																
HMPREF1322_RS06180	ı	Ppx/GppA family	NZ_AJZS01000066.1	22201	23108	ı	22243	ı	45	Over expr.	914.83	1.59	2.19E-12	DMC	10.21%	64.13%	53.91%	6.11E-07
		phosphatase																
HMPREF1322_RS06180	I	Ppx/GppA family	NZ_AJZS01000066.1	22201	23108	ı	22938	ı	737	Over expr.	914.83	1.59	2.19E-12	DMA	85.99%	37.41%	48.59%	4.56E-06
		phosphatase																
HMPREF1322_RS06180	ı	Ppx/GppA family	NZ_AJZS01000066.1	22201	23108	ı	22943	+	742	Over expr.	914.83	1.59	2.19E-12	DMC	70.43%	31.90%	38.53%	2.21E-05
		phosphatase																

"DE analysis, results from the differential expression analysis; Distance Meth, distance of the methylated position to the gene start site in base pairs, negative values indicate upstream location; DM analysis, results from the differential methylation analysis; ExH, growth in excess hemin; LFC, log 2 fold change; LIH, growth in limited hemin; Strand Expr, strand of the gene; Strand Meth, strand of the methylated position.

the two conditions was the hemin concentration: all other variables were constant in these continuous culture experiments. Previous research found that lactate utilization (in *Haemophilus influenzae and Staphylococcus aureus*) and the ABC transport of iron, manganese, and/or zinc ions across the membrane (e.g., in *Yersinia pestis, Salmonella enterica* and *Streptococcus* spp.) are linked to increased virulence (52–54). In our study, differential methylation in lactate utilization and ABC transporter genes co-occurred with their decreased expression in excess hemin conditions. We hypothesize that the decreased expression of these genes in excess hemin, and conversely their relative increased expression in limited hemin, could be related to *P. gingivalis* scavenging of nutrients according to their availability in the growth environment. Functional assessment of a methylation-mediated response to hemin is however necessary and will be the scope of future experiments.

Porphyromonas gingivalis possesses the Al-2 [encoded by luxS (HMPREF1322_RS03160, PG0498) (55-58); quorum sensing system]. The expression of LuxS is cell density-dependent. James et al. (57) suggested that luxS (PG0498 in P. gingivalis W83) is required for hemin uptake since a luxS isogenic mutant is affected in genes involved in hemin/iron acquisition (57). Furthermore, separate microarray and transcriptome analysis of the luxS mutant (59, 60) indicated the involvement of quorum sensing in hemin utilization in P. gingivalis, specifically through upregulation of hmuY and hmuR in DluxS. In our results, both hmuY and hmuR are under-expressed, to different extents, in excess hemin. It is therefore possible that increased cell density afforded by increased environmental hemin may play a role in the regulation of gene expression observed in this study. Limiting hemin conditions caused a decrease in cell density prior to achieving steady state in our results (Fig. 2). We hypothesize that this could be due to hemin limitation not being optimal for *P. gingivalis* growth. Alternatively, the starting OD may be skewed by the presence of dead cells in the inoculating culture, where these are later removed in the chemostat run.

In conclusion, using Nanopore sequencing, we were able to characterize for the first time the epigenetic landscape of *P. gingivalis* W50, and to compare epigenetic variation to changes in gene expression. We showed that iron availability in the bacterium's microenvironment can lead to discrete DNA methylation changes potentially impacting the expression of genes related to growth and virulence in humans. Future work is needed to experimentally dissect the role of DNA methylation on the observed gene expression changes in *P. gingivalis*. Furthermore, there is a need to better characterize the diversity of motifs targeted by different DNMTs, including from *P. gingivalis*. A more comprehensive characterization of DNMTs and their targeted motifs in the bacterial world will allow better future exploring of DNA methylation in *P. gingivalis* with Oxford Nanopore.

ACKNOWLEDGMENTS

We are grateful to the Medical Research Council of United Kingdom for the grant: MR/P012175/2. We thank the teams at the genome sequencing centers for assistance, and Mr Darioush Yarand and the Rosalind KCL high performance Linux cluster system administration team for help resolving file space and software installation queries.

M.A.C. and V.R. conceptualized the study. M.A.C, V.R., D.A.D., and J.T.B. provided resources. M.A.C., V.R., and J.T.B. supervised the study. R.C. and J.A.-O. implemented the methodology, J.A.-O. performed experiments, and R.C. carried out formal analysis and software implementation. J.J.V., F.R.-A., S.J., D.A.D., P.D.M., and V.R. contributed to methodology, experiments, analysis, and results interpretation. R.C., J.A.-O., M.A.C., and J.T.B. drafted the manuscript, and all authors reviewed and edited the manuscript.

AUTHOR AFFILIATIONS

¹Department of Twin Research and Genetic Epidemiology, King's College London, London, United Kingdom

²Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London, London, United Kingdom

³Division of Oral Biology, School of Dentistry, University of Leeds, Leeds, United Kingdom ⁴The Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom

AUTHOR ORCIDs

Ricardo Costeira http://orcid.org/0000-0002-8316-5219

Joseph Aduse-Opoku http://orcid.org/0000-0003-2072-8771

Jon J. Vernon http://orcid.org/0000-0002-0072-9294

Francisco Rodriguez-Algarra http://orcid.org/0000-0002-4134-2141

Susan Joseph http://orcid.org/0000-0002-0297-5405

Deirdre A. Devine http://orcid.org/0000-0002-8037-9254

Philip D. Marsh (1) http://orcid.org/0000-0002-1203-4457

Vardhman Rakyan http://orcid.org/0000-0003-4523-5121

Michael A. Curtis http://orcid.org/0000-0002-1563-9953

Jordana T. Bell http://orcid.org/0000-0002-3858-5986

FUNDING

Funder	Grant(s)	Author(s)
UKRI Medical Research Council (MRC)	MR/P012175/2	Michael A. Curtis

AUTHOR CONTRIBUTIONS

Ricardo Costeira, Formal analysis, Investigation, Methodology, Software, Visualization, Writing – original draft, Writing – review and editing | Joseph Aduse-Opoku, Investigation, Methodology, Visualization, Writing – original draft, Writing – review and editing | Jon J. Vernon, Investigation, Visualization, Writing – review and editing | Francisco Rodriguez-Algarra, Investigation, Writing – review and editing | Susan Joseph, Investigation, Writing – review and editing | Deirdre A. Devine, Investigation, Resources, Writing – review and editing | Philip D. Marsh, Investigation, Writing – review and editing | Vardhman Rakyan, Conceptualization, Investigation, Resources, Supervision, Writing – review and editing | Michael A. Curtis, Conceptualization, Funding acquisition, Resources, Supervision, Writing – original draft, Writing – review and editing | Jordana T. Bell, Methodology, Resources, Supervision, Visualization, Writing – original draft, Writing – review and editing

DATA AVAILABILITY STATEMENT

The Nanopore and Illumina RNA sequencing data generated for this study have been deposited in the European Nucleotide Archive (ENA) at EMBL-EBI under accession number PRJEB60468.

ADDITIONAL FILES

The following material is available online.

Supplemental Material

Supplemental Note (mSystems01193-22-S0001.docx). Supplemental Note with Figures A-L.

Table S1 (mSystems01193-22-s0002.xlsx). Genes over-expressed in excess hemin conditions (>1.5 LFC, FDR = 5%).

Table S2 (mSystems01193-22-s0003.xlsx). Genes under-expressed in excess hemin conditions (<-1.5 LFC, FDR = 5%).

Table S3 (mSystems01193-22-s0004.xlsx). GO molecular functions over-expressed in excess hemin conditions (based on 40 genes, FDR = 10%).

Table S4 (mSystems01193-22-s0005.xlsx). GO molecular functions under-expressed in excess hemin conditions (based on 8 genes, FDR = 10%).

Table S5 (mSystems01193-22-s0006.xlsx). 'GATC'-DMMs identified in *P. gingivalis* W50, selecting for minimum $10 \times (A)$ or $100 \times (B)$ coverage and mean 5% methylation difference between experimental conditions (FDR = 5%).

Table S6 (mSystems01193-22-s0007.xlsx). DMAs (6mA) identified in *P. gingivalis* W50, selecting for minimum $100 \times$ coverage and mean 5% methylation difference between experimental conditions (FDR = 5%).

Table S7 (mSystems01193-22-s0008.xlsx). DMCs (5mC) identified in *P. gingivalis* W50, selecting for minimum $100\times$ coverage and mean 5% methylation difference between experimental conditions (FDR = 5%).

Table S8 (mSystems01193-22-s0009.xlsx). Genes over-expressed in excess hemin conditions with 'GATC'-DMMs (>1.5 LFC, >5% methylation difference, FDR = 5%).

Table S9 (mSystems01193-22-s0010.xlsx). Genes under-expressed in excess hemin conditions with 'GATC'-DMMs (<-1.5 LFC, >5% methylation difference, FDR = 5%).

REFERENCES

- Cui Y, Tian G, Li R, Shi Y, Zhou T, Yan Y. 2023. Epidemiological and sociodemographic transitions of severe periodontitis incidence, prevalence, and disability-adjusted life years for 21 world regions and globally from 1990 to 2019: an age-period-cohort analysis. J Periodontol 94:193–203. https://doi.org/10.1002/JPER.22-0241
- Dominy SS, Lynch C, Ermini F, Benedyk M, Marczyk A, Konradi A, Nguyen M, Haditsch U, Raha D, Griffin C, Holsinger LJ, Arastu-Kapur S, Kaba S, Lee A, Ryder Ml, Potempa B, Mydel P, Hellvard A, Adamowicz K, Hasturk H, Walker GD, Reynolds EC, Faull RLM, Curtis MA, Dragunow M, Potempa J. 2019. Porphyromonas gingivalis in Alzheimer's disease brains: evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv 5:eaau3333. https://doi.org/10.1126/sciadv.aau3333
- Sedghi LM, Bacino M, Kapila YL. 2021. Periodontal disease: the good, the bad, and the unknown. Front Cell Infect Microbiol 11:766944. https://doi. org/10.3389/fcimb.2021.766944
- Hajishengallis G. 2022. Interconnection of periodontal disease and comorbidities: evidence, mechanisms, and implications. Periodontol 2000 89:9–18. https://doi.org/10.1111/prd.12430
- Hajishengallis G, Liang S, Payne MA, Hashim A, Jotwani R, Eskan MA, McIntosh ML, Alsam A, Kirkwood KL, Lambris JD, Darveau RP, Curtis MA. 2011. Low-abundance biofilm species orchestrates inflammatory periodontal disease through the commensal microbiota and complement. Cell Host Microbe 10:497–506. https://doi.org/10.1016/j.chom. 2011.10.006
- Payne MA, Hashim A, Alsam A, Joseph S, Aduse-Opoku J, Wade WG, Curtis MA. 2019. Horizontal and vertical transfer of oral microbial dysbiosis and periodontal disease. J Dent Res 98:1503–1510. https://doi. org/10.1177/0022034519877150
- Lunar Silva I, Cascales E. 2021. Molecular strategies underlying Porphyromonas gingivalis virulence. J Mol Biol 433:166836. https://doi. org/10.1016/j.jmb.2021.166836
- Haurat MF, Aduse-Opoku J, Rangarajan M, Dorobantu L, Gray MR, Curtis MA, Feldman MF. 2011. Selective sorting of cargo proteins into bacterial membrane vesicles. J Biol Chem 286:1269–1276. https://doi.org/10. 1074/jbc.M110.185744
- Smalley JW, Thomas MF, Birss AJ, Withnall R, Silver J. 2004. A combination of both arginine- and lysine-specific gingipain activity of Porphyromonas gingivalis is necessary for the generation of the micro-oxo bishaem-containing pigment from Haemoglobin. Biochem J 379:833–840. https://doi.org/10.1042/BJ20031221
- Smalley JW, Olczak T. 2017. Heme acquisition mechanisms of *Porphyro-monas gingivalis* strategies used in a Polymicrobial community in a Heme-limited host environment. Mol Oral Microbiol 32:1–23. https://doi. org/10.1111/omi.12149

- Anaya-Bergman C, Rosato A, Lewis JP. 2015. Iron- and hemin-dependent gene expression of *Porphyromonas gingivalis*. Mol Oral Microbiol 30:39– 61. https://doi.org/10.1111/omi.12066
- Veith PD, Luong C, Tan KH, Dashper SG, Reynolds EC. 2018. Outer membrane vesicle proteome of *Porphyromonas gingivalis* is differentially modulated relative to the outer membrane in response to heme availability. J Proteome Res 17:2377–2389. https://doi.org/10.1021/acs. jproteome.8b00153
- Lamont RJ, Jenkinson HF. 1998. Life below the gum line: pathogenic mechanisms of *Porphyromonas gingivalis*. Microbiol Mol Biol Rev 62:1244–1263. https://doi.org/10.1128/MMBR.62.4.1244-1263.1998
- Curtis MA, Aduse Opoku J, Rangarajan M, Gallagher A, Sterne JAC, Reid CR, Evans HEA, Samuelsson B. 2002. Attenuation of the virulence of *Porphyromonas gingivalis* by using a specific synthetic kgp protease inhibitor. Infect Immun 70:6968–6975. https://doi.org/10.1128/IAI.70.12. 6968-6975.2002
- McKee AS, McDermid AS, Baskerville A, Dowsett AB, Ellwood DC, Marsh PD. 1986. Effect of Hemin on the physiology and virulence of *Bacteroides gingivalis* W50. Infect Immun 52:349–355. https://doi.org/10.1128/iai.52. 2.349-355.1986
- Mattos-Graner RO, Duncan MJ. 2017. Two-component signal Transduction systems in oral bacteria. J Oral Microbiol 9:1400858. https://doi.org/10.1080/20002297.2017.1400858
- Jiang C, Yang D, Hua T, Hua Z, Kong W, Shi Y. 2021. A PorX/PorY and σ^P Feedforward regulatory loop controls gene expression essential for *Porphyromonas gingivalis* virulence. mSphere 6:e0042821. https://doi.org/10.1128/mSphere.00428-21
- Yang D, Jiang C, Ning B, Kong W, Shi Y. 2021. Correction: the PorX/PorY system is a virulence factor of *Porphyromonas gingivalis* and mediates the activation of the type IX secretion system. J Biol Chem 296:100750. https://doi.org/10.1016/j.jbc.2021.100750
- Murphy TR, Xiao R, Hamilton-Brehm SD. 2021. Hybrid genome de novo assembly with Methylome analysis of the anaerobic Thermophilic subsurface bacterium thermanaerosceptrum fracticalcis strain DRI-13^T. BMC Genomics 22:209. https://doi.org/10.1186/s12864-021-07535-z
- Tourancheau A, Mead EA, Zhang XS, Fang G. 2021. Discovering multiple types of DNA methylation from bacteria and microbiome using nanopore sequencing. Nat Methods 18:491–498. https://doi.org/10. 1038/s41592-021-01109-3
- Marsh PD, McDermid AS, McKee AS, Baskerville A. 1994. The effect of growth rate and haemin on the virulence and proteolytic activity of Porphyromonas gingivalis W50. Microbiology (Reading) 140 (Pt 4):861– 865. https://doi.org/10.1099/00221287-140-4-861
- Mahmud A, Delhomme N, Nandi S, Fällman M. 2021. Prokseq for complete analysis of RNA-Seq data from Prokaryotes. Bioinformatics 37:126–128. https://doi.org/10.1093/bioinformatics/btaa1063

- Wingett SW, Andrews S. 2018. Fastq screen: a tool for multi-genome mapping and quality control. F1000Res 7:1338. https://doi.org/10. 12688/f1000research.15931.2
- Chen S, Huang T, Zhou Y, Han Y, Xu M, Gu J. 2017. Afterqc: automatic filtering, trimming, error removing and quality control for fastq data. BMC Bioinformatics 18:80. https://doi.org/10.1186/s12859-017-1469-3
- Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with bowtie 2. Nat Methods 9:357–359. https://doi.org/10.1038/nmeth.1923
- Liao Y, Smyth GK, Shi W. 2014. Featurecounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30:923–930. https://doi.org/10.1093/bioinformatics/ btt656
- Wang L, Wang S, Li W. 2012. RSeQC: quality control of RNA-Seq experiments. Bioinformatics 28:2184–2185. https://doi.org/10.1093/ bioinformatics/bts356
- Byrne A, Beaudin AE, Olsen HE, Jain M, Cole C, Palmer T, DuBois RM, Forsberg EC, Akeson M, Vollmers C. 2017. Nanopore long-read RNA-seq reveals widespread transcriptional variation among the surface receptors of individual B cells. Nat Commun 8:16027. https://doi.org/10. 1038/ncomms16027
- Bayega A, Oikonomopoulos S, Gregoriou M-E, Tsoumani KT, Giakountis A, Wang YC, Mathiopoulos KD, Ragoussis J. 2021. Nanopore long-read RNA-Seq and absolute quantification delineate transcription dynamics in early embryo development of an insect pest. Sci Rep 11:7878. https:// doi.org/10.1038/s41598-021-86753-7
- Stoiber M, Quick J, Egan R, Eun Lee J, Celniker S, Neely RK, Loman N, Pennacchio LA, Brown J. 2017 *De novo* identification of DNA modifications enabled by genome-guided nanopore signal processing. Bioinformatics. https://doi.org/10.1101/094672
- Lawrence M, Gentleman R, Carey V. 2009. Rtracklayer: An R package for Interfacing with genome Browsers. Bioinformatics 25:1841–1842. https://doi.org/10.1093/bioinformatics/btp328
- Lawrence M, Huber W, Pagès H, Aboyoun P, Carlson M, Gentleman R, Morgan MT, Carey VJ. 2013. Software for computing and annotating genomic ranges. PLoS Comput Biol 9:e1003118. https://doi.org/10.1371/journal.pcbi.1003118
- Love MI, Huber W, Anders S. 2014. Moderated estimation of fold change and dispersion for RNA-Seq data with DEseq2. Genome Biol 15:550. https://doi.org/10.1186/s13059-014-0550-8
- Robinson MD, McCarthy DJ, Smyth GK. 2010. Edger: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26:139–140. https://doi.org/10.1093/bioinformatics/btp616
- Nelson KE, Fleischmann RD, DeBoy RT, Paulsen IT, Fouts DE, Eisen JA, Daugherty SC, Dodson RJ, Durkin AS, Gwinn M, Haft DH, Kolonay JF, Nelson WC, Mason T, Tallon L, Gray J, Granger D, Tettelin H, Dong H, Galvin JL, Duncan MJ, Dewhirst FE, Fraser CM. 2003. Complete genome sequence of the oral pathogenic bacterium *Porphyromonas gingivalis* strain W83. J Bacteriol 185:5591–5601. https://doi.org/10.1128/JB.185. 18.5591-5601.2003
- Darling AE, Mau B, Perna NT. 2010. Progressivemauve: multiple genome alignment with gene gain, loss and rearrangement. PLoS One 5:e11147. https://doi.org/10.1371/journal.pone.0011147
- Ge SX, Jung D, Yao R. 2020. Shinygo: a graphical gene-set enrichment tool for animals and plants. Bioinformatics 36:2628–2629. https://doi. org/10.1093/bioinformatics/btz931
- Bailey TL, Williams N, Misleh C, Li WW. 2006. MEME: discovering and analyzing DNA and protein sequence motifs. Nucleic Acids Res 34:W369–73. https://doi.org/10.1093/nar/gkl198
- Kondo Y, Ohara N, Sato K, Yoshimura M, Yukitake H, Naito M, Fujiwara T, Nakayama K. 2010. Tetratricopeptide repeat protein-associated proteins contribute to the virulence of *Porphyromonas gingivalis*. Infect Immun 78:2846–2856. https://doi.org/10.1128/IAI.01448-09
- Lewis JP, Dawson JA, Hannis JC, Muddiman D, Macrina FL. 1999. Hemoglobinase activity of the lysine gingipain protease (kgp) of Porphyromonas gingivalis W83. J Bacteriol 181:4905–4913. https://doi. org/10.1128/JB.181.16.4905-4913.1999
- Sztukowska M, Bugno M, Potempa J, Travis J, Kurtz DM. 2002. Role of Rubrerythrin in the oxidative stress response of *Porphyromonas* gingivalis. Mol Microbiol 44:479–488. https://doi.org/10.1046/j.1365-2958.2002.02892.x

- Gabarrini G, Grasso S, Winkelhoff AJ, Dijl JM. 2020. Gingimaps: protein localization in the oral pathogen. Microbiol Mol Biol Rev 84:e00032. https://doi.org/10.1128/MMBR.00032-19
- 43. Wang H, Peng W, Zhang G, Jiang M, Zhao J, Zhao X, Pan Y, Lin L. 2022. Role of Pg0192 and Pg0193 in the modulation of pro-inflammatory Cytokines in Macrophages in response to *Porphyromonas gingivalis*. Eur J Oral Sci 130:e12851. https://doi.org/10.1111/eos.12851
- Veith PD, Glew MD, Gorasia DG, Reynolds EC. 2017. Type IX secretion: the generation of bacterial cell surface coatings involved in virulence, gliding motility and the degradation of complex biopolymers. Mol Microbiol 106:35–53. https://doi.org/10.1111/mmi.13752
- Lasica AM, Ksiazek M, Madej M, Potempa J. 2017. The type IX secretion system (T9Ss): highlights and recent insights into its structure and function. Front Cell Infect Microbiol 7:215. https://doi.org/10.3389/fcimb. 2017.00215
- Casadesús J, Low D. 2006. Epigenetic gene regulation in the bacterial world. Microbiol Mol Biol Rev 70:830–856. https://doi.org/10.1128/ MMBR.00016-06
- Beaulaurier J, Schadt EE, Fang G. 2019. Deciphering bacterial epigenomes using modern sequencing technologies. Nat Rev Genet 20:157– 172. https://doi.org/10.1038/s41576-018-0081-3
- Low DA, Weyand NJ, Mahan MJ. 2001. Roles of DNA adenine methylation in regulating bacterial gene expression and virulence. Infect Immun 69:7197–7204. https://doi.org/10.1128/IAI.69.12.7197-7204.2001
- Nemoto TK, Ohara-Nemoto Y. 2016. Exopeptidases and gingipains in Porphyromonas gingivalis as prerequisites for its amino acid metabolism. Jpn Dent Sci Rev 52:22–29. https://doi.org/10.1016/j.jdsr.2015.08.002
- Lewis JP, Iyer D, Anaya-Bergman C. 2009. Adaptation of *Porphyromonas gingivalis* to Microaerophilic conditions involves increased consumption of Formate and reduced utilization of lactate. Microbiology (Reading) 155:3758–3774. https://doi.org/10.1099/mic.0.027953-0
- Moradali MF, Davey ME. 2021. Metabolic plasticity enables lifestyle transitions of *Porphyromonas gingivalis*. NPJ Biofilms Microbiomes 7:46. https://doi.org/10.1038/s41522-021-00217-4
- Garmory HS, Titball RW. 2004. Atp-binding cassette transporters are targets for the development of antibacterial vaccines and therapies. Infect Immun 72:6757–6763. https://doi.org/10.1128/IAI.72.12.6757-6763.2004
- Fuller JR, Vitko NP, Perkowski EF, Scott E, Khatri D, Spontak JS, Thurlow LR, Richardson AR. 2011. Identification of a lactate-quinone oxidoreductase in *Staphylococcus aureus* that is essential for virulence. Front Cell Infect Microbiol 1:19. https://doi.org/10.3389/fcimb.2011.00019
- Lichtenegger S, Bina I, Roier S, Bauernfeind S, Keidel K, Schild S, Anthony M, Reidl J. 2014. Characterization of lactate utilization and its implication on the physiology of *haemophilus influenzae*. Int J Med Microbiol 304:490–498. https://doi.org/10.1016/j.ijmm.2014.02.010
- Burgess NA, Kirke DF, Williams P, Winzer K, Hardie KR, Meyers NL, Aduse-Opoku J, Curtis MA, Cámara M. 2002. Luxs-dependent quorum sensing in *Porphyromonas gingivalis* modulates protease and haemagglutinin activities but is not essential for virulence. Microbiology (Reading) 148:763–772. https://doi.org/10.1099/00221287-148-3-763
- Chung WO, Park Y, Lamont RJ, McNab R, Barbieri B, Demuth DR. 2001.
 Signaling system in *Porphyromonas gingivalis* based on a Luxs protein. J Bacteriol 183:3903–3909. https://doi.org/10.1128/JB.183.13.3903-3909.
- James CE, Hasegawa Y, Park Y, Yeung V, Tribble GD, Kuboniwa M, Demuth DR, Lamont RJ. 2006. Luxs involvement in the regulation of genes coding for hemin and iron acquisition systems in *Porphyromonas* gingivalis. Infect Immun 74:3834–3844. https://doi.org/10.1128/IAI. 01768-05
- Maeda K, Tribble GD, Tucker CM, Anaya C, Shizukuishi S, Lewis JP, Demuth DR, Lamont RJ. 2008. A Porphyromonas gingivalis tyrosine phosphatase is a multifunctional regulator of virulence attributes. Mol Microbiol 69:1153–1164. https://doi.org/10.1111/j.1365-2958.2008. 06338.x
- Hirano T, Beck DAC, Demuth DR, Hackett M, Lamont RJ. 2012. Deep sequencing of *Porphyromonas gingivalis* and comparative transcriptome analysis of a Luxs mutant. Front Cell Infect Microbiol 2:79. https://doi. org/10.3389/fcimb.2012.00079

Downloaded from https://journals.asm.org/journal/msystems on 26 January 2024 by 2.126.43.57.

 Yuan L, Hillman JD, Progulske-Fox A. 2005. Microarray analysis of quorum-sensing-regulated genes in *Porphyromonas gingivalis*. Infect Immun 73:4146–4154. https://doi.org/10.1128/IAI.73.7.4146-4154.2005